| Year |
Citation |
Score |
| 2024 |
Wang F, Yu X, Qian J, Cao Y, Dong S, Zhan S, Lu Z, Bast RC, Song Q, Chen Y, Zhang Y, Zhou J. A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 74: 101077. PMID 38518726 DOI: 10.1016/j.drup.2024.101077 |
0.316 |
|
| 2022 |
Handley KF, Sims TT, Bateman NW, Glassman D, Foster KI, Lee S, Yao J, Yao H, Fellman BM, Liu J, Lu Z, Conrads KA, Hood BL, Barakat W, Zhao L, ... ... Bast RC, et al. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics. Jama Network Open. 5: e2236626. PMID 36239936 DOI: 10.1001/jamanetworkopen.2022.36626 |
0.345 |
|
| 2022 |
Irajizad E, Han CY, Celestino J, Wu R, Murage E, Spencer R, Dennison JB, Vykoukal J, Long JP, Do KA, Drescher C, Lu K, Lu Z, Bast RC, Hanash S, et al. A blood-based metabolite panel for distinguishing ovarian cancer from benign pelvic masses. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36037307 DOI: 10.1158/1078-0432.CCR-22-1113 |
0.304 |
|
| 2022 |
Boylan KLM, Petersen A, Starr TK, Pu X, Geller MA, Bast RC, Lu KH, Cavallaro U, Connolly DC, Elias KM, Cramer DW, Pejovic T, Skubitz APN. Development of a Multiprotein Classifier for the Detection of Early Stage Ovarian Cancer. Cancers. 14. PMID 35804849 DOI: 10.3390/cancers14133077 |
0.343 |
|
| 2022 |
Shi X, Yu X, Wang J, Bian S, Li Q, Fu F, Zou X, Zhang L, Bast RC, Lu Z, Guo L, Chen Y, Zhou J. SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK. Molecular Oncology. PMID 35278271 DOI: 10.1002/1878-0261.13208 |
0.396 |
|
| 2021 |
Blackman A, Mitchell J, Rowswell-Turner R, Singh R, Kim KK, Eklund E, Skates S, Bast RC, Messerlian G, Miller MC, Moore RG. Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 43: 355-365. PMID 34957977 DOI: 10.3233/TUB-211546 |
0.327 |
|
| 2021 |
Bast RC, Han CY, Lu Z, Lu KH. Next steps in the early detection of ovarian cancer. Communications Medicine. 1. PMID 34676377 DOI: 10.1038/s43856-021-00037-9 |
0.336 |
|
| 2021 |
Bildik G, Liang X, Sutton MN, Bast RC, Lu Z. DIRAS3: An Imprinted tumor suppressor gene that regulates RAS and PI3K-driven cancer growth, motility, autophagy and tumor dormancy. Molecular Cancer Therapeutics. PMID 34667114 DOI: 10.1158/1535-7163.MCT-21-0331 |
0.31 |
|
| 2021 |
Artibani M, Masuda K, Hu Z, Rauher PC, Mallett G, Wietek N, Morotti M, Chong K, KaramiNejadRanjbar M, Zois CE, Dhar S, El-Sahhar S, Campo L, Blagden SP, Damato S, ... ... Bast RC, et al. Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor initiating cells. Jci Insight. PMID 33945502 DOI: 10.1172/jci.insight.147929 |
0.356 |
|
| 2021 |
Fan D, Yang H, Mao W, Rask PJ, Pang L, Xu C, Vankayalapat H, Ahmed AA, Bast RC, Lu Z. A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin. Cancers. 13. PMID 33503955 DOI: 10.3390/cancers13030446 |
0.369 |
|
| 2020 |
Kim O, Park EY, Kwon SY, Shin S, Emerson RE, Shin YH, DeMayo FJ, Lydon JP, Coffey DM, Hawkins SM, Quilliam LA, Cheon DJ, Fernández FM, Nephew KP, Karpf AR, ... ... Bast RC, et al. Targeting progesterone signaling prevents metastatic ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 33262282 DOI: 10.1073/pnas.2013595117 |
0.375 |
|
| 2020 |
Bast RC, Lu Z, Han CY, Lu KH, Anderson KS, Drescher CW, Skates S. Biomarkers and Strategies for Early Detection of Ovarian Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 33051337 DOI: 10.1158/1055-9965.EPI-20-1057 |
0.317 |
|
| 2020 |
Gentry-Maharaj A, Blyuss O, Ryan A, Burnell M, Karpinskyj C, Gunu R, Kalsi JK, Dawnay A, Marino IP, Manchanda R, Lu K, Yang WL, Timms JF, Parmar M, Skates SJ, ... Bast RC, et al. Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. Cancers. 12. PMID 32708856 DOI: 10.3390/Cancers12071931 |
0.392 |
|
| 2020 |
Kim O, Park EY, Klinkebiel DL, Pack SD, Shin YH, Abdullaev Z, Emerson RE, Coffey DM, Kwon SY, Creighton CJ, Kwon S, Chang EC, Chiang T, Yatsenko AN, Chien J, ... ... Bast RC, et al. In vivo modeling of metastatic human high-grade serous ovarian cancer in mice. Plos Genetics. 16: e1008808. PMID 32497036 DOI: 10.1371/Journal.Pgen.1008808 |
0.45 |
|
| 2020 |
Blessing AM, Santiago-O'Farrill JM, Mao W, Pang L, Ning J, Pak D, Bollu LR, Rask P, Iles L, Yang H, Tran S, Elmir E, Bartholomeusz G, Langley R, Lu Z, ... Bast RC, et al. Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition. Cancer. PMID 32484926 DOI: 10.1002/Cncr.32985 |
0.486 |
|
| 2020 |
Kobayashi M, Katayama H, Irajizad E, Vykoukal JV, Fahrmann JF, Kundnani DL, Yu CY, Cai Y, Hsiao FC, Yang WL, Lu Z, Celestino J, Long JP, Do KA, Lu KH, ... ... Bast RC, et al. Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis. Cancers. 12. PMID 32092936 DOI: 10.3390/Cancers12020485 |
0.481 |
|
| 2020 |
Lu Z, Mso W, Santiago-O'Farrill JM, Yang H, Pang L, Ahmed AA, Vankayalapati H, Bast RC. Abstract 5210: Novel SIK2 inhibitors sensitize ovarian and breast cancer to PARP inhibitors Cancer Research. 80: 5210-5210. DOI: 10.1158/1538-7445.Am2020-5210 |
0.453 |
|
| 2020 |
Santiago-O'Farrill JM, Blessing AM, Becker SE, Lu Z, Bast RC. Abstract 4083: Crizotinib improves the therapeutic efficacy of olaparib in ovarian cancer Cancer Research. 80: 4083-4083. DOI: 10.1158/1538-7445.Am2020-4083 |
0.513 |
|
| 2019 |
Yang WL, Lu Z, Guo J, Fellman BM, Ning J, Lu KH, Menon U, Kobayashi M, Hanash SM, Celestino J, Skates SJ, Bast RC. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer. Cancer. PMID 31714597 DOI: 10.1002/Cncr.32582 |
0.463 |
|
| 2019 |
Santiago-O'Farrill JM, Weroha SJ, Hou X, Oberg AL, Heinzen EP, Maurer MJ, Pang L, Rask P, Amaravadi RK, Becker SE, Romero I, Rubio MJ, Matias-Guiu X, Santacana M, Llombart-Cussac A, ... ... Bast RC, et al. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. Cancer. PMID 31714594 DOI: 10.1002/Cncr.32600 |
0.437 |
|
| 2019 |
Guo J, Lu Z, Bast RC. Reply to Comment on "Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer" 2019, , 596: Markers for Early Detection of Ovarian Cancer. Cancers. 11. PMID 31540545 DOI: 10.3390/Cancers11091386 |
0.438 |
|
| 2019 |
Lyu T, Jiang Y, Jia N, Che X, Li Q, Yu Y, Hua K, Bast RC, Feng W. SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters. International Journal of Cancer. PMID 31503345 DOI: 10.1002/Ijc.32673 |
0.453 |
|
| 2019 |
Yang H, Shu Z, Jiang Y, Mao W, Pang L, Redwood A, Jeter-Jones SL, Jennings NB, Ornelas A, Zhou J, Rodriguez-Aguayo C, Bartholomeusz G, Iles LR, Zacharias NM, Millward SW, ... ... Bast RC, et al. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31391192 DOI: 10.1158/1078-0432.Ccr-18-3448 |
0.473 |
|
| 2019 |
Nebgen DR, Lu KH, Bast RC. Novel Approaches to Ovarian Cancer Screening. Current Oncology Reports. 21: 75. PMID 31346778 DOI: 10.1007/S11912-019-0816-0 |
0.462 |
|
| 2019 |
Andre F, Ismaila N, Henry NL, Somerfield MR, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Van Poznak C, Wolff AC, Stearns V. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900945. PMID 31150316 DOI: 10.1200/Jco.19.00945 |
0.302 |
|
| 2019 |
Sutton MN, Huang GY, Zhou J, Mao W, Langley R, Lu Z, Bast RC. Amino Acid Deprivation-Induced Autophagy Requires Upregulation of DIRAS3 through Reduction of E2F1 and E2F4 Transcriptional Repression. Cancers. 11. PMID 31052266 DOI: 10.3390/Cancers11050603 |
0.467 |
|
| 2019 |
Guo J, Yang WL, Pak D, Celestino J, Lu KH, Ning J, Lokshin AE, Cheng Z, Lu Z, Bast RC. Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer. Cancers. 11. PMID 31035430 DOI: 10.3390/Cancers11050596 |
0.442 |
|
| 2019 |
Sutton MN, Huang GY, Liang X, Sharma R, Reger AS, Mao W, Pang L, Rask PJ, Lee K, Gray JP, Hurwitz AM, Palzkill T, Millward SW, Kim C, Lu Z, ... Bast RC, et al. DIRAS3-Derived Peptide Inhibits Autophagy in Ovarian Cancer Cells by Binding to Beclin1. Cancers. 11. PMID 31003488 DOI: 10.3390/Cancers11040557 |
0.46 |
|
| 2019 |
Simmons AR, Fourkala EO, Gentry-Maharaj A, Ryan A, Sutton MN, Baggerly K, Zheng H, Lu KH, Jacobs I, Skates S, Menon U, Bast RC. Complementary longitudinal serum biomarkers to CA125 for early detection of ovarian cancer. Cancer Prevention Research (Philadelphia, Pa.). PMID 30967390 DOI: 10.1158/1940-6207.Capr-18-0377 |
0.398 |
|
| 2019 |
Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, et al. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. PMID 30835824 DOI: 10.1002/Cncr.32004 |
0.46 |
|
| 2019 |
Karuturi MS, Holmes HM, Lei X, Johnson M, Barcenas CH, Cantor SB, Gallick GE, Bast RC, Giordano SH. Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer. Journal of Geriatric Oncology. PMID 30795923 DOI: 10.1016/J.Jgo.2019.01.024 |
0.369 |
|
| 2019 |
Skubitz AP, Boylan KL, Geschwind KA, Cao Q, Starr TK, Geller MA, Celestino J, Bast RC, Lu KH, Koopmeiners JS. Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multi-Protein Classifier for Ovarian Cancer Detection. Cancer Prevention Research (Philadelphia, Pa.). PMID 30709840 DOI: 10.1158/1940-6207.Capr-18-0221 |
0.454 |
|
| 2019 |
Mao W, Peters HL, Sutton MN, Orozco AF, Pang L, Yang H, Lu Z, Bast RC. The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts. Cancer. PMID 30620384 DOI: 10.1002/Cncr.31935 |
0.486 |
|
| 2019 |
Woolas RP, Oram DH, Jeyarajah AR, Bast RC, Jacobs IJ. Ovarian cancer identified through screening with serum markers but not by pelvic imaging. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 9: 497-501. PMID 11240818 DOI: 10.1046/J.1525-1438.1999.99073.X |
0.444 |
|
| 2019 |
Bast RC, Yu Y, Xu FJ, Le XF, Mills GB. Molecular approaches to management of epithelial ovarian cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 10: 2-7. PMID 11240724 DOI: 10.1046/J.1525-1438.2000.99502.X |
0.407 |
|
| 2019 |
Skubitz APN, Boylan KLM, Geschwind K, Cao Q, Starr TK, Geller MA, Celestino J, Bast RC, Lu KH, Koopmeiners JS. Abstract AP08: DEVELOPMENT OF A MULTI-PROTEIN CLASSIFIER FOR OVARIAN CANCER DETECTION BY SIMULTANEOUS MEASUREMENT OF 92 SERUM PROTEINS ON PROSEEK MULTIPLEX ONCOLOGY II PLATES Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Ap08 |
0.483 |
|
| 2019 |
Bischoff F, Mathieu K, Vargas J, Pang L, Kulp A, Dewing A, Liu X, Bast R, Hazle J, Zhang M. Abstract P6-01-05: Detection of HER2 positive tumor cells using functionalized iron oxide nanoparticles Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P6-01-05 |
0.333 |
|
| 2019 |
Blessing AM, Mao W, Pang L, Rask P, Lu Z, Bast RC. Abstract 4263: Autophagic ovarian cancer cells exhibit substantially enhanced sensitivity to ALK inhibition Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4263 |
0.479 |
|
| 2019 |
Luan B, Zhao H, Bast RC, Lu Z, Yu Y. Abstract 3816: Corilagin could help to overcome PARP inhibitor resistance by inhibiting ERK signaling pathways Cancer Research. 79: 3816-3816. DOI: 10.1158/1538-7445.Sabcs18-3816 |
0.404 |
|
| 2019 |
Guo J, Yang W, Celestino J, Lu K, Lokshin AE, Lu Z, Bast RC. Abstract 912: Macrophage inhibitory factor (MIF), osteopontin (OPN) and anti-interleukin-8 (IL-8) autoantibodies (AAb) complement CA125 for detection of early-stage ovarian cancer Cancer Research. 79: 912-912. DOI: 10.1158/1538-7445.Am2019-912 |
0.429 |
|
| 2019 |
Santiago-O'Farrill JM, Weroha SJ, Hou X, Pang L, Rask P, Lu Z, Bast RC. Abstract 4768: PARP inhibitor-induced autophagy provides an adaptive mechanism of drug resistance in preclinical models of ovarian cancer Cancer Research. 79: 4768-4768. DOI: 10.1158/1538-7445.Am2019-4768 |
0.479 |
|
| 2018 |
Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, Bast RC. Cell Origins of High-Grade Serous Ovarian Cancer. Cancers. 10. PMID 30424539 DOI: 10.3390/Cancers10110433 |
0.415 |
|
| 2018 |
Elias KM, Guo J, Bast RC. Early Detection of Ovarian Cancer. Hematology/Oncology Clinics of North America. 32: 903-914. PMID 30390764 DOI: 10.1016/J.Hoc.2018.07.003 |
0.457 |
|
| 2018 |
Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Investigational New Drugs. PMID 30311036 DOI: 10.1007/S10637-018-0672-Z |
0.391 |
|
| 2018 |
Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Artholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC. Paclitaxel Sensitivity of Ovarian Cancer can be enhanced by knocking down Pairs of Kinases that regulate MAP4 Phosphorylation and Microtubule Stability. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30084832 DOI: 10.1158/1078-0432.Ccr-18-0504 |
0.359 |
|
| 2018 |
Karuturi MS, Holmes HM, Lei X, Johnson M, Barcenas CH, Cantor SB, Gallick GE, Bast RC, Giordano SH. Potentially inappropriate medication use in older patients with breast and colorectal cancer. Cancer. PMID 29689595 DOI: 10.1002/Cncr.31403 |
0.368 |
|
| 2018 |
Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC, Fu S, Hu W, Sood AK. Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Frontiers in Oncology. 8: 9. PMID 29456965 DOI: 10.3389/Fonc.2018.00009 |
0.36 |
|
| 2018 |
Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, ... ... Bast RC, et al. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nature Communications. 9: 476. PMID 29396402 DOI: 10.1038/S41467-017-02811-7 |
0.404 |
|
| 2018 |
Sutton MN, Yang H, Huang GY, Fu C, Pontikos M, Wang Y, Mao W, Pang L, Yang M, Liu J, Parker-Thornburg J, Lu Z, Bast RC. RAS-related GTPases DIRAS1 and DIRAS2 induce autophagic cancer cell death and are required for autophagy in murine ovarian cancer cells. Autophagy. 1-47. PMID 29368982 DOI: 10.1080/15548627.2018.1427022 |
0.462 |
|
| 2018 |
Bischoff FZ, Mathieu KB, Pang L, Kulp A, Lu Z, Huber D, Hazle JD, Bast RC, Paciotti G. Detection and measurement of HER2+ breast cancer cells using tumor-targeted iron oxide nanoparticles and magnetic relaxometry. Journal of Clinical Oncology. 36: e13019-e13019. DOI: 10.1200/Jco.2018.36.15_Suppl.E13019 |
0.391 |
|
| 2018 |
Yang W, Lu Z, Lu KH, Menon U, Kobayashi M, Hanash S, Skates S, Bast RC. Abstract LB-176: HE4 antigen-autoantibody complexes complement CA125 for detecting early stage ovarian cancer and can be elevated with CA125 in preclinical ovarian cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-176 |
0.476 |
|
| 2018 |
Lu Z, Mao W, Pang L, Santiago-O'Farrill JM, Yang H, Ahmed A, Vankayalapati H, Bast RC. Abstract 324: SIK2 inhibitors regulate DNA repair pathway and sensitize ovarian cancer to PARP1 inhibitors Cancer Research. 78: 324-324. DOI: 10.1158/1538-7445.Am2018-324 |
0.416 |
|
| 2018 |
Sutton MN, Huang GY, Zhou J, Lu Z, Bast RC. Abstract 1325: DIRAS3 (ARHI) is required for amino acid-mediated autophagy and nutrient deprivation in dormant ovarian cancers Cancer Research. 78: 1325-1325. DOI: 10.1158/1538-7445.Am2018-1325 |
0.514 |
|
| 2017 |
Lin CW, Yang H, Sanchez SR, Mao W, Pang L, Beckingham KM, Bast RC, Weisman RB. In Vivo Optical Detection and Spectral Triangulation of Carbon Nanotubes. Acs Applied Materials & Interfaces. PMID 29131572 DOI: 10.1021/Acsami.7B12916 |
0.66 |
|
| 2017 |
Krop I, Ismaila N, Andre F, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Wolff AC, Stearns V. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017740472. PMID 28692382 DOI: 10.1200/Jco.2017.74.0472 |
0.356 |
|
| 2017 |
Mathieu KB, Bedi DG, Thrower SL, Qayyum A, Bast RC. Screening for ovarian cancer: imaging challenges and opportunities for improvement. Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology. PMID 28639753 DOI: 10.1002/Uog.17557 |
0.445 |
|
| 2017 |
Yang WL, Gentry-Maharaj A, Simmons AR, Ryan A, Fourkala EO, Lu Z, Baggerly KA, Zhao Y, Lu K, Bowtell DDL, Jacobs I, Skates SJ, He WW, Menon U, Bast RC. Elevation of TP53 Autoantibody Prior to CA125 in Preclinical Invasive Epithelial Ovarian Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28637689 DOI: 10.1158/1078-0432.Ccr-17-0284 |
0.483 |
|
| 2017 |
Yang WL, Lu Z, Bast RC. The role of biomarkers in the management of epithelial ovarian cancer. Expert Review of Molecular Diagnostics. PMID 28468520 DOI: 10.1080/14737159.2017.1326820 |
0.466 |
|
| 2017 |
Taylor C, Mannion D, Miranda F, Karaminejadranjbar M, Herrero-Gonzalez S, Hellner K, Zheng Y, Bartholomeusz G, Bast RC, Ahmed AA. Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells. Oncotarget. PMID 28152500 DOI: 10.18632/Oncotarget.14910 |
0.476 |
|
| 2017 |
Vankayalapati H, Yerramreddy V, Zhou J, Handler JA, Appalaneni RP, Kancherla RR, Wu RJ, Takemori H, Whitehurst A, Jazaeri AA, Coleman RL, Lu Z, Bast RC. Abstract LB-296: Discovery of ARN-3261 as a potent, selective, orally available SIK2 inhibitor for treating ovarian, endometrial, primary peritoneal, fallopian tube, and triple negative breast cancers Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-296 |
0.507 |
|
| 2017 |
Yang H, Zhang S, Mao W, Ahmed AA, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Le X, Lu Z, Bast RC. Abstract 3564: Silencing pfkfb2 enhances paclitaxel sensitivity by modulating metabolism of p53 wt ovarian and breast cancer cells and xenografts Cancer Research. 77: 3564-3564. DOI: 10.1158/1538-7445.Am2017-3564 |
0.418 |
|
| 2017 |
Santiago-O'Farrill JM, Essien S, Figueroa M, Pang L, Amaravadi R, Lu Z, Bast RC. Abstract 3317: Autophagy protects ovarian cancer cells from olaparib-induced toxicity Cancer Research. 77: 3317-3317. DOI: 10.1158/1538-7445.Am2017-3317 |
0.445 |
|
| 2017 |
Blessing AM, Wang Y, Mao W, Pang L, Lu Z, Bast RC. Abstract 3313: Autophagic ovarian cancer cells exhibit substantially enhanced sensitivity to Crizotinib Cancer Research. 77: 3313-3313. DOI: 10.1158/1538-7445.Am2017-3313 |
0.51 |
|
| 2017 |
Mathieu K, Lu Z, Yang H, Pang L, Kulp A, Hazle J, Bast RC. Abstract 1864: Feasibility of magnetic relaxometry for early ovarian cancer detection: preliminary evaluation of sensitivity and specificity in cell culture and in mice Cancer Research. 77: 1864-1864. DOI: 10.1158/1538-7445.Am2017-1864 |
0.384 |
|
| 2016 |
Blessin AM, Rajapakshe K, Reddy Bollu L, Shi Y, White MA, Pham AH, Lin C, Jonsson P, Cortes CJ, Cheung E, La Spada AR, Bast RC, Merchant FA, Coarfa C, Frigo DE. Transcriptional Regulation of Core Autophagy and Lysosomal Genes by the Androgen Receptor Promotes Prostate Cancer Progression. Autophagy. 0. PMID 27977328 DOI: 10.1080/15548627.2016.1268300 |
0.351 |
|
| 2016 |
Ornelas A, McCullough CR, Lu Z, Zacharias NM, Kelderhouse LE, Gray J, Yang H, Engel BJ, Wang Y, Mao W, Sutton MN, Bhattacharya PK, Bast RC, Millward SW. Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models. Bmc Cancer. 16: 824. PMID 27784287 DOI: 10.1186/S12885-016-2850-8 |
0.375 |
|
| 2016 |
Zhou J, Alfraidi A, Zhang S, Santiago-O'Farrill J, Yerramreddy V, Alsaadid A, Ahmed AA, Yang H, Liu J, Mao W, Takemori H, Wang Y, Vankayalapati H, Lu Z, Bast RC. A novel compound ARN-3236 inhibits Salt Inducible Kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27678456 DOI: 10.1158/1078-0432.Ccr-16-1562 |
0.462 |
|
| 2016 |
Hellner K, Miranda F, Fotso Chedom D, Herrero-Gonzalez S, Hayden DM, Tearle R, Artibani M, KaramiNejadRanjbar M, Williams R, Gaitskell K, Elorbany S, Xu R, Laios A, Buiga P, Ahmed K, ... ... Bast RC, et al. Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies. Ebiomedicine. PMID 27492892 DOI: 10.1016/J.Ebiom.2016.06.048 |
0.423 |
|
| 2016 |
Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, Karaminejadranjbar M, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, ... ... Bast RC, et al. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell. PMID 27478041 DOI: 10.1016/J.Ccell.2016.06.020 |
0.467 |
|
| 2016 |
Leung F, Bernardini MQ, Brown MD, Zheng Y, Molina R, Bast RC, Davis G, Serra S, Diamandis EP, Kulasingam V. Validation of a novel biomarker panel for the detection of ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 27448593 DOI: 10.1158/1055-9965.Epi-15-1299 |
0.453 |
|
| 2016 |
Gao M, Ma Y, Bast RC, Li Y, Wan L, Liu Y, Sun Y, Fang Z, Zhang L, Wang X, Wei Z. Epac1 knockdown inhibits the proliferation of ovarian cancer cells by inactivating AKT/Cyclin D1/CDK4 pathway in vitro and in vivo. Medical Oncology (Northwood, London, England). 33: 73. PMID 27277757 DOI: 10.1007/S12032-016-0786-0 |
0.48 |
|
| 2016 |
Simmons AR, Clarke CH, Badgwell DB, Lu Z, Sokoll LJ, Lu KH, Zhang Z, Bast RC, Skates SJ. Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 27206285 DOI: 10.1097/Igc.0000000000000737 |
0.471 |
|
| 2016 |
Morgado M, Sutton MN, Simmons M, Warren CR, Lu Z, Constantinou PE, Liu J, Francis LL, Conlan RS, Bast RC, Carson DD. Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB. Oncotarget. PMID 26918940 DOI: 10.18632/Oncotarget.7652 |
0.479 |
|
| 2016 |
Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, van Poznak C, Bast RC, Hayes DF. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26858339 DOI: 10.1200/Jco.2015.65.2289 |
0.33 |
|
| 2016 |
Redis RS, Vela LE, Lu W, Ferreira de Oliveira J, Ivan C, Rodriguez-Aguayo C, Adamoski D, Pasculli B, Taguchi A, Chen Y, Fernandez AF, Valledor L, Van Roosbroeck K, Chang S, Shah M, ... ... Bast RC, et al. Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Molecular Cell. PMID 26853146 DOI: 10.1016/J.Molcel.2016.01.015 |
0.358 |
|
| 2016 |
Bast RC, Raamanathan A, Gentry-Maharaj A, Skates S, Baggerly KA, Fourkala R, Ryan A, Zhang Z, Menon U, Jacobs I. Validation of a multi-marker panel for early detection of ovarian cancer. Journal of Clinical Oncology. 34: 5570-5570. DOI: 10.1200/Jco.2016.34.15_Suppl.5570 |
0.44 |
|
| 2016 |
Liang L, Mercado-Uribe I, Niu N, Jiang Y, Cheng W, Broaddus R, Bast R, Mills G, Sood AK, Liu J. Abstract B22: Establishment of Patient-Derived Xenograft (PDX) Models of Ovarian Cancer Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-B22 |
0.449 |
|
| 2016 |
Lu Z, Orozco AF, Yang H, Sutton MN, Wang Y, Mao W, Levine DA, Bast RC. Abstract PR18: Survival of ARHI-induced dormant autophagic cell death in vivo requires permissive levels of VEGF, IL-8, and IGF-1 in the tumor microenvironment. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-Pr18 |
0.524 |
|
| 2016 |
Sutton MN, Lu Z, Bast RC. Abstract A43: DIRAS1 and DIRAS2 are tumor suppressor candidates that inhibit cell growth, motility, and proliferation while regulating autophagy in ovarian cancer. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-A43 |
0.479 |
|
| 2016 |
Niu N, Zhang J, Zhang N, Mercado-Uribe I, Tao F, Han Z, Pathak S, Multani A, Kuang J, Yao J, Bast R, Sood A, Hung M, Liu J. Abstract LB-119: Single-cell live imaging of paclitaxel-resistant cancer cell generation Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-119 |
0.451 |
|
| 2016 |
Yang H, Wang X, Ahmed A, Iles L, Bartholomeusz G, Lu Z, Bast RC. Abstract 4670: Combinations of kinase siRNAs potentiates paclitaxel sensitivity in ovarian cancer Cancer Research. 76: 4670-4670. DOI: 10.1158/1538-7445.Am2016-4670 |
0.469 |
|
| 2016 |
Kobayashi M, Boldt CR, Yang W, Aguilar-Bonavides C, Wang H, Lu Z, Bast RC, Hanash SM. Abstract 438: Development of an autoantibody panel that reflects disease pathogenesis in ovarian cancer Cancer Research. 76: 438-438. DOI: 10.1158/1538-7445.Am2016-438 |
0.499 |
|
| 2016 |
Sutton MN, Lu Z, Yang H, Huang G, Wang Y, Mao W, Bast RC. Abstract 3659: DIRAS1 and DIRAS2 are novel ovarian cancer tumor suppressors that regulate cell growth, motility and autophagy Cancer Research. 76: 3659-3659. DOI: 10.1158/1538-7445.Am2016-3659 |
0.507 |
|
| 2016 |
Zhou J, Alfredi A, Zhang S, Santiago-O’Farrill JM, Ahmed AA, Yang H, Mao W, Wang Y, Vankayalapati H, Lu Z, Bast RC. Abstract 3032: A novel compound ARN-3236 inhibits SIK2 and sensitizes ovarian cancer to paclitaxel Cancer Research. 76: 3032-3032. DOI: 10.1158/1538-7445.Am2016-3032 |
0.519 |
|
| 2016 |
Lu Z, Orozco A, Mao W, Wang Y, Sutton MN, Yang H, Levine DA, Bast RC. Abstract 1151: IL-8, VEGF and IGF-1 play the important role in ARHI mediated-tumor dormancy in ovarian cancer Cancer Research. 76: 1151-1151. DOI: 10.1158/1538-7445.Am2016-1151 |
0.469 |
|
| 2015 |
Yang H, Das P, Yu Y, Mao W, Wang Y, Baggerly K, Wang Y, Marquez RT, Bedi A, Liu J, Fishman D, Lu Z, Bast RC. NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms. Oncotarget. PMID 26689988 DOI: 10.18632/Oncotarget.6576 |
0.511 |
|
| 2015 |
Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 26588231 DOI: 10.1097/Igc.0000000000000586 |
0.476 |
|
| 2015 |
Ma Y, Wei Z, Bast RC, Wang Z, Li Y, Gao M, Liu Y, Wang X, Guo C, Zhang L, Wang X. Downregulation of TRIM27 expression inhibits the proliferation of ovarian cancer cells in vitro and in vivo. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 26568293 DOI: 10.1038/Labinvest.2015.132 |
0.487 |
|
| 2015 |
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews. Cancer. 15: 668-79. PMID 26493647 DOI: 10.1038/Nrc4019 |
0.475 |
|
| 2015 |
Chen J, Bai M, Ning C, Xie B, Zhang J, Liao H, Xiong J, Tao X, Yan D, Xi X, Chen X, Yu Y, Bast RC, Zhang Z, Feng Y, et al. Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway. Oncogene. PMID 26364616 DOI: 10.1038/Onc.2015.316 |
0.419 |
|
| 2015 |
Washington MN, Suh G, Orozco AF, Sutton MN, Yang H, Wang Y, Mao W, Millward S, Ornelas A, Atkinson N, Liao W, Bast RC, Lu Z. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. Cell Death & Disease. 6: e1836. PMID 26247722 DOI: 10.1038/Cddis.2015.208 |
0.458 |
|
| 2015 |
Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, Hicks DG, Hill EG, Liu MC, Lucas W, Mayer IA, Mennel RG, Symmans WF, Hayes DF, Harris LN. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26195705 DOI: 10.1200/Jco.2015.61.1459 |
0.349 |
|
| 2015 |
Zhang S, Lu Z, Mao W, Ahmed AA, Yang H, Zhou J, Jennings N, Rodriguez-Aguayo C, Lopez-Berestein G, Miranda R, Qiao W, Baladandayuthapani V, Li Z, Sood AK, Liu J, ... ... Bast RC, et al. CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. Plos One. 10: e0131833. PMID 26146988 DOI: 10.1371/Journal.Pone.0131833 |
0.489 |
|
| 2015 |
Shadfan BH, Simmons AR, Simmons GW, Ho A, Wong J, Lu KH, Bast RC, McDevitt JT. A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care. Cancer Prevention Research (Philadelphia, Pa.). 8: 37-48. PMID 25388014 DOI: 10.1158/1940-6207.Capr-14-0248 |
0.402 |
|
| 2015 |
Zhang S, Lu Z, Unruh AK, Ivan C, Baggerly KA, Calin GA, Li Z, Bast RC, Le XF. Clinically relevant microRNAs in ovarian cancer. Molecular Cancer Research : McR. 13: 393-401. PMID 25304686 DOI: 10.1158/1541-7786.Mcr-14-0424 |
0.361 |
|
| 2015 |
Boldt C, Simmons A, Wang H, Baggerly K, Bast R, Hanash S. Abstract AS12: Integrating genomics, transcriptomics, and proteomics for the discovery of novel biomarkers to complement CA125 in ovarian cancer early detection Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-As12 |
0.459 |
|
| 2015 |
Yang H, Das P, Mao W, Marquez RT, Lu Z, Bast RC. Abstract 5105: The imprinted tumor suppressor gene NDN inhibits cell motility in ovarian cancer by reactivating FAK and RhoA Cancer Research. 75: 5105-5105. DOI: 10.1158/1538-7445.Am2015-5105 |
0.466 |
|
| 2015 |
Lu Z, Orozco AF, Sutton M, Yan W, Mao W, Bast R. Abstract 4987: IL8, VEGF and IGF-1 rescue ovarian cancer cells undergoing ARHI-mediated- autophagic cell death Cancer Research. 75: 4987-4987. DOI: 10.1158/1538-7445.Am2015-4987 |
0.47 |
|
| 2015 |
Lu Z, Mao W, Wang Y, Levine DA, Bast RC. Abstract 4028: ARHI plays a critical role in ovarian cancer tumor dormancy by inhibition of angiogenesis switch Cancer Research. 75: 4028-4028. DOI: 10.1158/1538-7445.Am2015-4028 |
0.432 |
|
| 2015 |
Lyu T, Jia N, Wang J, Bast RC, Baak JP, Hua K, Feng W. Abstract 3827: Histone methytransferase SMYD3 promotes invasion in ovarian carcinoma spheroids Cancer Research. 75: 3827-3827. DOI: 10.1158/1538-7445.Am2015-3827 |
0.461 |
|
| 2015 |
Morgado M, Sutton MN, Simmons M, Liu J, Lu Z, Papadopoulos PE, Bast RC, Carson DD. Abstract 3456: MUC16/CA125, TNFα and IFNγ are co-expressed in malignant gynecologic neoplasms Cancer Research. 75: 3456-3456. DOI: 10.1158/1538-7445.Am2015-3456 |
0.493 |
|
| 2015 |
Yang W, Simmons A, Lu Z, Baggerly K, Lu K, Gentry-Maharaj A, Menon U, Jacobs I, Bast RC. Abstract 2838: TP53 autoantibody can detect CA125 screen negative ovarian cancer cases and can be elevated prior to CA125 in preclinical ovarian cancer Cancer Research. 75: 2838-2838. DOI: 10.1158/1538-7445.Am2015-2838 |
0.484 |
|
| 2015 |
Suh GK, Hennessy BT, Verhaak R, Yang JY, Mills GB, Bast RC. Molecular targets for epithelial ovarian cancer Molecular Oncology: Causes of Cancer and Targets For Treatment. 606-618. DOI: 10.1017/CBO9781139046947.055 |
0.328 |
|
| 2014 |
Lu Z, Baquero MT, Yang H, Yang M, Reger AS, Kim C, Levine DA, Clarke CH, Liao WS, Bast RC. DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells. Autophagy. 10: 1071-92. PMID 24879154 DOI: 10.4161/Auto.28577 |
0.493 |
|
| 2014 |
Deniger DC, Maiti SN, Mi T, Switzer KC, Ramachandran V, Hurton LV, Ang S, Olivares S, Rabinovich BA, Huls MH, Lee DA, Bast RC, Champlin RE, Cooper LJ. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5708-19. PMID 24833662 DOI: 10.1158/1078-0432.Ccr-13-3451 |
0.316 |
|
| 2014 |
Lu Z, Yang H, Sutton MN, Yang M, Clarke CH, Liao WS, Bast RC. ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7. Cell Death and Differentiation. 21: 1275-89. PMID 24769729 DOI: 10.1038/Cdd.2014.48 |
0.457 |
|
| 2014 |
Holman LL, Lu KH, Bast RC, Hernandez MA, Bodurka DC, Skates S, Sun CC. Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. American Journal of Obstetrics and Gynecology. 210: 257.e1-6. PMID 24246524 DOI: 10.1016/J.Ajog.2013.11.022 |
0.372 |
|
| 2014 |
Alfredi A, Zhang S, Mao W, Wang Y, Takemori H, Lu Z, Bast RC, Vankayalapati H. Abstract 749: Highly potent and orally available SIK2 inhibitors block growth of human ovarian cancer cells in culture and xenografts Cancer Research. 74: 749-749. DOI: 10.1158/1538-7445.Am2014-749 |
0.466 |
|
| 2014 |
Tao X, Jin H, Zhang Z, Bast RC, Feng Y, Yu Y. Abstract 3762: Downregulation of TRPC3 enhances sensitivity to cisplatin and inhibits motility in epithelial ovarian cancer Cancer Research. 74: 3762-3762. DOI: 10.1158/1538-7445.Am2014-3762 |
0.498 |
|
| 2014 |
Yang H, Das P, Yu Y, Baggerly K, Wang Y, Mao W, Marquez RT, Lu Z, Liu J, Bast RC. Abstract 2311: NDN, an imprinted tumor suppressor gene inhibits ovarian cancer cell growth and motility and is downregulated by genetic and epigenetic mechanisms Cancer Research. 74: 2311-2311. DOI: 10.1158/1538-7445.Am2014-2311 |
0.508 |
|
| 2013 |
Lyu T, Jia N, Wang J, Yan X, Yu Y, Lu Z, Bast RC, Hua K, Feng W. Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma. Epigenetics. 8: 1330-46. PMID 24135786 DOI: 10.4161/Epi.26675 |
0.443 |
|
| 2013 |
Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, ... ... Bast RC, et al. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 119: 3454-61. PMID 23983047 DOI: 10.1097/01.Ogx.0000442828.54138.67 |
0.459 |
|
| 2013 |
Zhang Z, Zhu Y, Lai Y, Wu X, Feng Z, Yu Y, Bast RC, Wan X, Xi X, Feng Y. Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway. International Journal of Oncology. 43: 1194-204. PMID 23921511 DOI: 10.3892/Ijo.2013.2054 |
0.471 |
|
| 2013 |
Simmons AR, Baggerly K, Bast RC. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. Oncology (Williston Park, N.Y.). 27: 548-56. PMID 23909069 |
0.411 |
|
| 2013 |
Romero I, Sun CC, Wong KK, Bast RC, Gershenson DM. Low-grade serous carcinoma: new concepts and emerging therapies. Gynecologic Oncology. 130: 660-6. PMID 23707670 DOI: 10.1016/J.Ygyno.2013.05.021 |
0.377 |
|
| 2013 |
Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC, Liu J. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 23: 815-22. PMID 23669443 DOI: 10.1097/Igc.0B013E31828F7A24 |
0.442 |
|
| 2013 |
Tao X, Zhao N, Jin H, Zhang Z, Liu Y, Wu J, Bast RC, Yu Y, Feng Y. FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3. Endocrine-Related Cancer. 20: 415-29. PMID 23580589 DOI: 10.1530/Erc-12-0005 |
0.484 |
|
| 2013 |
Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC, Fu S, Hu W, Sood AK. Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Frontiers in Oncology. 3: 58. PMID 23519775 DOI: 10.3389/Fonc.2013.00058 |
0.448 |
|
| 2013 |
Lu Z, Bast RC. The tumor suppressor gene ARHI (DIRAS3) inhibits ovarian cancer cell migration through multiple mechanisms. Cell Adhesion & Migration. 7: 232-6. PMID 23357870 DOI: 10.4161/Cam.23648 |
0.468 |
|
| 2013 |
Diamandis EP, Bast RC, Lopez-Otín C. Conquering cancer in our lifetime: new diagnostic and therapeutic trends. Clinical Chemistry. 59: 1-3. PMID 23204223 DOI: 10.1373/Clinchem.2012.186940 |
0.448 |
|
| 2013 |
Diamandis EP, Bast RC, Gold P, Chu TM, Magnani JL. Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9. Clinical Chemistry. 59: 22-31. PMID 23204222 DOI: 10.1373/Clinchem.2012.187047 |
0.424 |
|
| 2013 |
Raamanathan A, Holman LL, Urbauer DL, Baggerly KA, Shen Y, Bast RC, Lu KH. Clinical factors affecting HE4 and CA125 in women at high risk of developing ovarian cancer. Journal of Clinical Oncology. 31: 1569-1569. DOI: 10.1200/Jco.2013.31.15_Suppl.1569 |
0.373 |
|
| 2013 |
Yang H, Wang X, Ahmed AA, Lu Z, Bast RC. Abstract 953: Knockdown of kinases that regulate microtubule stability and centrosome function enhance paclitaxel sensitivity in multiple ovarian cancer cell lines. Cancer Research. 73: 953-953. DOI: 10.1158/1538-7445.Am2013-953 |
0.413 |
|
| 2013 |
Zhang S, Mao W, Sood AK, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Li Z, Bast RC, Le X. Abstract 5433: Knockdown of the glycolytic enzyme PFKFB2 induces growth inhibition and enhances paclitaxel sensitivity in ovarian cancer cells. Cancer Research. 73: 5433-5433. DOI: 10.1158/1538-7445.Am2013-5433 |
0.489 |
|
| 2013 |
Zhang Z, Zhu Y, Xu X, Xi X, Bast RC, Yu Y, Feng Y. Abstract 4766: Follicle stimulating hormone (FSH) inhibits apoptosis in ovarian cancer cell through regulating OCT4 stem cell signal pathway. Cancer Research. 73: 4766-4766. DOI: 10.1158/1538-7445.Am2013-4766 |
0.475 |
|
| 2013 |
Shadfan B, Raamanathan A, Simmons G, Bast RC, McDevitt JT. Abstract 3495: Multiplexed detection of early-stage ovarian cancer biomarkers using a microfluidic bead-based immunosensor. Cancer Research. 73: 3495-3495. DOI: 10.1158/1538-7445.Am2013-3495 |
0.474 |
|
| 2013 |
Raamanathan A, Lu Z, Bast RC, Skates SJ. Abstract 3473: Intra-person and inter-person biomarker variation for modeling longitudinal values of ovarian cancer early detection biomarkers. Cancer Research. 73: 3473-3473. DOI: 10.1158/1538-7445.Am2013-3473 |
0.457 |
|
| 2013 |
Le X, Ling H, Mao M, Zhang X, Zhang S, Calin GA, Wu Y, Bast RC. Abstract 3055: miR-495 functions as a novel regulator of the estrogen and progesterone receptorsin human breast cancers. Cancer Research. 73: 3055-3055. DOI: 10.1158/1538-7445.Am2013-3055 |
0.34 |
|
| 2013 |
Washington MN, Suh G, Orozco AF, Yang M, Wang Y, Atkinson N, Liao W, Lu Z, Bast R. Abstract 1680: ARHI-induced autophagy enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. Cancer Research. 73: 1680-1680. DOI: 10.1158/1538-7445.Am2013-1680 |
0.462 |
|
| 2013 |
Sutton MN, Lu Z, Bast RC. Abstract 1669: DIRAS family members inhibit cell growth and proliferation while inducing autophagy in human ovarian cancer cells. Cancer Research. 73: 1669-1669. DOI: 10.1158/1538-7445.Am2013-1669 |
0.445 |
|
| 2013 |
Holman L, Lu K, Hernandez M, Bast R, Neal S, Skates S, Gershenson D, Sun C. Changes in perceptions of screening over time among average-risk women undergoing ovarian cancer screening using the risk of ovarian cancer algorithm Gynecologic Oncology. 130. DOI: 10.1016/J.Ygyno.2013.04.133 |
0.385 |
|
| 2012 |
Jia L, Zhang S, Ye Y, Li X, Mercado-Uribe I, Bast RC, Liu J. Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells. Cancer Letters. 326: 176-82. PMID 22902993 DOI: 10.1016/J.Canlet.2012.08.004 |
0.409 |
|
| 2012 |
Fu S, Li Y, Huang J, Liu T, Hong Z, Chen A, Bast RC, Kavanagh JJ, Gershenson DM, Sood AK, Hu W. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biology & Therapy. 13: 1034-41. PMID 22895067 DOI: 10.4161/Cbt.21045 |
0.51 |
|
| 2012 |
Le XF, Almeida MI, Mao W, Spizzo R, Rossi S, Nicoloso MS, Zhang S, Wu Y, Calin GA, Bast RC. Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer. Plos One. 7: e41170. PMID 22829924 DOI: 10.1371/Journal.Pone.0041170 |
0.347 |
|
| 2012 |
Xu J, Shetty PB, Feng W, Chenault C, Bast RC, Issa JP, Hilsenbeck SG, Yu Y. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. Bmc Cancer. 12: 243. PMID 22695491 DOI: 10.1186/1471-2407-12-243 |
0.372 |
|
| 2012 |
Bast RC, Mills GB. Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancer. Cancer Discovery. 2: 16-8. PMID 22585163 DOI: 10.1158/2159-8290.Cd-11-0323 |
0.456 |
|
| 2012 |
Bast RC, Skates S, Lokshin A, Moore RG. Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 22: S5-8. PMID 22543921 DOI: 10.1097/Igc.0B013E318251C97D |
0.349 |
|
| 2012 |
Raamanathan A, Simmons GW, Christodoulides N, Floriano PN, Furmaga WB, Redding SW, Lu KH, Bast RC, McDevitt JT. Programmable bio-nano-chip systems for serum CA125 quantification: Toward ovarian cancer diagnostics at the point-of-care Cancer Prevention Research. 5: 706-716. PMID 22490510 DOI: 10.1158/1940-6207.Capr-11-0508 |
0.441 |
|
| 2012 |
Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, ... ... Bast RC, et al. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecologic Oncology. 126: 47-53. PMID 22487539 DOI: 10.1016/J.Ygyno.2012.04.006 |
0.402 |
|
| 2012 |
Romero I, Bast RC. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology. 153: 1593-602. PMID 22416079 DOI: 10.1210/En.2011-2123 |
0.489 |
|
| 2012 |
Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC, Park ST, Pusztai L, Calin GA. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 118: 2603-14. PMID 22370716 DOI: 10.1002/Cncr.26565 |
0.404 |
|
| 2012 |
Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC, Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. American Journal of Obstetrics and Gynecology. 206: 349.e1-7. PMID 22301440 DOI: 10.1016/J.Ajog.2011.12.028 |
0.36 |
|
| 2012 |
Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, Bast RC. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. American Journal of Obstetrics and Gynecology. 206: 351.e1-8. PMID 22284961 DOI: 10.1016/J.Ajog.2011.12.029 |
0.361 |
|
| 2012 |
Bast RC. Molecular approaches to personalizing management of ovarian cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. viii5-viii15. PMID 22180401 DOI: 10.1093/Annonc/Mdr516 |
0.505 |
|
| 2012 |
Ahmed AA, Becker CM, Bast RC. The origin of ovarian cancer. Bjog : An International Journal of Obstetrics and Gynaecology. 119: 134-6. PMID 22168761 DOI: 10.1111/J.1471-0528.2011.03149.X |
0.469 |
|
| 2012 |
Russell P, Hennessy BT, Li J, Carey MS, Bast RC, Freeman T, Venkitaraman AR. Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest. Oncogene. 31: 2450-60. PMID 22056875 DOI: 10.1038/Onc.2011.431 |
0.385 |
|
| 2012 |
Bast RC. Biomarkers for ovarian cancer: new technologies and targets to address persistently unmet needs. Cancer Biomarkers : Section a of Disease Markers. 8: 161-6. PMID 22045350 DOI: 10.3233/Cbm-2011-0209 |
0.443 |
|
| 2012 |
Moore LE, Pfeiffer RM, Zhang Z, Lu KH, Fung ET, Bast RC. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer. 118: 91-100. PMID 21717433 DOI: 10.1002/Cncr.26241 |
0.465 |
|
| 2012 |
Badgwell DB, Lu Z, Le K, Gao F, Yang M, Suh GK, Bao JJ, Das P, Andreeff M, Chen W, Yu Y, Ahmed AA, S-L Liao W, Bast RC. The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene. 31: 68-79. PMID 21643014 DOI: 10.1038/Onc.2011.213 |
0.452 |
|
| 2012 |
Bast RC, Mills GB. Alterations in oncogenes, tumor suppressor genes, and growth factors associated with epithelial ovarian cancers. Methods in Molecular Medicine. 39: 37-48. PMID 21340756 DOI: 10.1385/1-59259-071-3:37 |
0.503 |
|
| 2012 |
Raamanathan A, Shadfan B, Simmons GW, Ho A, Bast RC, McDevitt J. Abstract 4067: Integrated microfluidic bead-based immunosensor for multiplexed determinations of ovarian cancer biomarkers at the point-of-care Cancer Research. 72: 4067-4067. DOI: 10.1158/1538-7445.Am2012-4067 |
0.443 |
|
| 2012 |
Nolen BM, Lomakin A, Bast R, Lu K, Marrangoni A, Lokshin AE. Abstract 3573: Urine and serum biomarkers as early detection tools for ovarian cancer Cancer Research. 72: 3573-3573. DOI: 10.1158/1538-7445.Am2012-3573 |
0.461 |
|
| 2012 |
Zhang S, Mao W, Ahmed AA, Li Z, Le X, Bast RC. Abstract 3057: CDK5 modulates the cell cycle, apoptosis and paclitaxel sensitivity in human ovarian cancer cells with wild-type p53 function Cancer Research. 72: 3057-3057. DOI: 10.1158/1538-7445.Am2012-3057 |
0.424 |
|
| 2012 |
Yang H, Das PM, Lu Z, Yu Y, Marquez RT, Liao W, Bast RC. Abstract 2182: Epigenetic regulation and growth suppression by NDN, an imprinted tumor suppressor gene whose expression is decreased in epithelial ovarian cancers Cancer Research. 72: 2182-2182. DOI: 10.1158/1538-7445.Am2012-2182 |
0.479 |
|
| 2012 |
Holman L, Lu K, Hernandez M, Bast R, Bodurka D, Skates S, Gershenson D, Sun C. Perception of risk, cancer worry, anxiety, and acceptability of screening among low-risk women undergoing ovarian cancer screening with the risk of ovarian cancer algorithm Gynecologic Oncology. 125. DOI: 10.1016/J.Ygyno.2011.12.281 |
0.397 |
|
| 2011 |
Zhang Z, Skates SJ, Sokoll LJ, Lu Z, Clarke CH, Hernandez MA, Lu KH, Bast RC. A multivariate longitudinal algorithm for early detection of ovarian cancer using multiple biomarkers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 5031. PMID 28023709 DOI: 10.1200/Jco.2011.29.15_Suppl.5031 |
0.439 |
|
| 2011 |
Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews. Cancer. 11: 719-25. PMID 21941283 DOI: 10.1038/Nrc3144 |
0.432 |
|
| 2011 |
Su JL, Cheng X, Yamaguchi H, Chang YW, Hou CF, Lee DF, Ko HW, Hua KT, Wang YN, Hsiao M, Chen PB, Hsu JM, Bast RC, Hortobagyi GN, Hung MC. FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization. Cancer Research. 71: 6878-87. PMID 21911455 DOI: 10.1158/0008-5472.Can-11-0295 |
0.383 |
|
| 2011 |
Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. Journal of the National Cancer Institute. 103: 1403-22. PMID 21813412 DOI: 10.1093/Jnci/Djr280 |
0.494 |
|
| 2011 |
Ahmed AA, Wang X, Lu Z, Goldsmith J, Le XF, Grandjean G, Bartholomeusz G, Broom B, Bast RC. Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel. Cancer Research. 71: 5806-17. PMID 21775522 DOI: 10.1158/0008-5472.Can-11-0025 |
0.357 |
|
| 2011 |
Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Z, Lu KH, Bast RC. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecologic Oncology. 122: 548-53. PMID 21708402 DOI: 10.1016/J.Ygyno.2011.06.002 |
0.429 |
|
| 2011 |
Le XF, Bast RC. Src family kinases and paclitaxel sensitivity. Cancer Biology & Therapy. 12: 260-9. PMID 21646863 DOI: 10.4161/Cbt.12.4.16430 |
0.49 |
|
| 2011 |
Bast RC, Spriggs DR. More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. Gynecologic Oncology. 121: 429-30. PMID 21601106 DOI: 10.1016/J.Ygyno.2011.04.032 |
0.453 |
|
| 2011 |
Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA, Bast RC. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer. 117: 4424-38. PMID 21491416 DOI: 10.1002/Cncr.26073 |
0.48 |
|
| 2011 |
Mandal PK, Gao F, Lu Z, Ren Z, Ramesh R, Birtwistle JS, Kaluarachchi KK, Chen X, Bast RC, Liao WS, McMurray JS. Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. Journal of Medicinal Chemistry. 54: 3549-63. PMID 21486047 DOI: 10.1021/Jm2000882 |
0.31 |
|
| 2011 |
Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 117: 1661-9. PMID 21472713 DOI: 10.1002/Cncr.25701 |
0.4 |
|
| 2011 |
Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prevention Research (Philadelphia, Pa.). 4: 375-83. PMID 21372037 DOI: 10.1158/1940-6207.Capr-10-0193 |
0.38 |
|
| 2011 |
Cramer DW, Bast RC, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prevention Research (Philadelphia, Pa.). 4: 365-74. PMID 21372036 DOI: 10.1158/1940-6207.Capr-10-0195 |
0.441 |
|
| 2011 |
Ahmed AA, Goldsmith J, Fokt I, Le XF, Krzysko KA, Lesyng B, Bast RC, Priebe W. A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. Cancer Chemotherapy and Pharmacology. 68: 1033-44. PMID 21340606 DOI: 10.1007/S00280-011-1575-2 |
0.398 |
|
| 2011 |
Zou CF, Jia L, Jin H, Yao M, Zhao N, Huan J, Lu Z, Bast RC, Feng Y, Yu Y. Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel. Bmc Cancer. 11: 22. PMID 21244707 DOI: 10.1186/1471-2407-11-22 |
0.479 |
|
| 2011 |
Ahmed AA, Bast RC, Bowtell D, Goldsmith J. Abstract 4822: Nonsense mediated decay defines deleterious TP53 mutations and tumor aggressiveness in ovarian cancer Cancer Research. 71: 4822-4822. DOI: 10.1158/1538-7445.Am2011-4822 |
0.41 |
|
| 2011 |
Tao X, Jin H, Bast RC, Liu Y, Yu Y, Feng Y. Abstract 4540: Follicle-stimulating hormone (FSH) enhances the proliferation of epithelial ovarian cancer cells by activating transient receptor potential channel C3 (TRPC3) Cancer Research. 71: 4540-4540. DOI: 10.1158/1538-7445.Am2011-4540 |
0.491 |
|
| 2011 |
Le X, Wu Y, Spizzo R, Yoo S, Wang J, Calin GA, Bast RC. Abstract 4000: Trastuzumab targeting of HER2 upregulates miRNA-194 and downregulates profilin 2 and DNMT3A in HER2 positive breast cancer Cancer Research. 71: 4000-4000. DOI: 10.1158/1538-7445.Am2011-4000 |
0.351 |
|
| 2011 |
Liao WS, Lu Z, Gao F, Yang M, Bast RC. Abstract 3779: ARHI-induced autophagy is mediated through activation of FoxO3a and induction of its target genes to promote the formation of autophagic complexes Cancer Research. 71: 3779-3779. DOI: 10.1158/1538-7445.Am2011-3779 |
0.402 |
|
| 2011 |
Lu Z, Liao WS, Yang M, Gao F, Bast R. Abstract 2097: ARHI (DiRAS3): A novel component in the formation of the autophagy initiation complex Cancer Research. 71: 2097-2097. DOI: 10.1158/1538-7445.Am2011-2097 |
0.364 |
|
| 2010 |
Yang H, Lu X, Qian J, Xu F, Hu Y, Yu Y, Bast RC, Li J. Imprinted tumor suppressor gene ARHI induces apoptosis correlated with changes in DNA methylation in pancreatic cancer cells. Molecular Medicine Reports. 3: 581-7. PMID 21472283 DOI: 10.3892/Mmr_00000301 |
0.459 |
|
| 2010 |
Le XF, Merchant O, Bast RC, Calin GA. The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society. 3: 137-47. PMID 21209780 DOI: 10.1007/S12307-010-0037-4 |
0.397 |
|
| 2010 |
Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Molecular Cancer Therapeutics. 9: 3186-99. PMID 20889728 DOI: 10.1158/1535-7163.Mct-10-0563 |
0.484 |
|
| 2010 |
Bast RC, Markman M. Chemotherapy: A new standard combination for recurrent ovarian cancer? Nature Reviews. Clinical Oncology. 7: 559-60. PMID 20877420 DOI: 10.1038/Nrclinonc.2010.152 |
0.425 |
|
| 2010 |
Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, ... ... Bast RC, et al. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell. 18: 109-21. PMID 20708153 DOI: 10.1016/J.Ccr.2010.06.018 |
0.443 |
|
| 2010 |
Le XF, Mao W, Lu Z, Carter BZ, Bast RC. Dasatinib induces autophagic cell death in human ovarian cancer. Cancer. 116: 4980-90. PMID 20629079 DOI: 10.1002/Cncr.25426 |
0.459 |
|
| 2010 |
Bast RC. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer. 116: 2850-3. PMID 20564390 DOI: 10.1002/Cncr.25203 |
0.43 |
|
| 2010 |
Bast RC, Mills GB. Personalizing therapy for ovarian cancer: BRCAness and beyond. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3545-8. PMID 20547987 DOI: 10.1200/Jco.2010.28.5791 |
0.465 |
|
| 2010 |
Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH, Liu J. Stanniocalcin 1 and ovarian tumorigenesis. Journal of the National Cancer Institute. 102: 812-27. PMID 20484106 DOI: 10.1093/Jnci/Djq127 |
0.489 |
|
| 2010 |
Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, Skates SJ. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. American Journal of Obstetrics and Gynecology. 203: 228.e1-6. PMID 20471625 DOI: 10.1016/J.Ajog.2010.03.043 |
0.398 |
|
| 2010 |
Donach M, Yu Y, Artioli G, Banna G, Feng W, Bast RC, Zhang Z, Nicoletto MO. Combined use of biomarkers for detection of ovarian cancer in high-risk women. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 31: 209-15. PMID 20393825 DOI: 10.1007/S13277-010-0032-X |
0.471 |
|
| 2010 |
Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC, Lokshin AE. Development of a multimarker assay for early detection of ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2159-66. PMID 20368574 DOI: 10.1200/Jco.2008.19.2484 |
0.446 |
|
| 2010 |
Hennessey VG, Rosner GL, Bast RC, Chen MY. A Bayesian approach to dose-response assessment and synergy and its application to in vitro dose-response studies. Biometrics. 66: 1275-83. PMID 20337630 DOI: 10.1111/J.1541-0420.2010.01403.X |
0.317 |
|
| 2010 |
Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL, Bast RC. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. Journal of Hematology & Oncology. 3: 9. PMID 20222977 DOI: 10.1186/1756-8722-3-9 |
0.382 |
|
| 2010 |
Zheng J, Mercado-Uribe I, Rosen DG, Chang B, Liu P, Yang G, Malpica A, Naora H, Auersperg N, Mills GB, Bast RC, Liu J. Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle (Georgetown, Tex.). 9: 140-6. PMID 20016289 DOI: 10.4161/Cc.9.1.10264 |
0.361 |
|
| 2010 |
Huang S, Chang IS, Lin W, Ye W, Luo RZ, Lu Z, Lu Y, Zhang K, Liao WS, Tao T, Bast RC, Chen X, Yu Y. ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins. Bioscience Reports. 30: 159-68. PMID 19435463 DOI: 10.1042/Bsr20090008 |
0.302 |
|
| 2010 |
Thigpen JT, Alberts D, Birrer M, Copeland L, Coleman RL, Markman M, Bast RC, Eisenhauer EL, Fleming G, Fracasso PM, Gershenson DM, Herzog T, Monk BJ, Ozols RF, Rustin G, et al. Current challenges and future directions in the management of ovarian cancer: Proceedings of the first global workshop on ovarian cancer Clinical Ovarian Cancer. 3: 81-97. DOI: 10.3816/Coc.2010.N.015 |
0.47 |
|
| 2010 |
Lu KH, Skates S, Bevers TB, Newland W, Moore RG, Leeds L, Harris S, Adeyinka OW, Fritsche HA, Bast RC. A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). Journal of Clinical Oncology. 28: 5003-5003. DOI: 10.1200/Jco.2010.28.15_Suppl.5003 |
0.411 |
|
| 2010 |
Lu Z, Liao WS, Suh GK, Bast RC. Abstract 4679: Integrin and FAK signaling regulate ARHI-induced autophagy Cancer Research. 70: 4679-4679. DOI: 10.1158/1538-7445.Am10-4679 |
0.482 |
|
| 2010 |
Nolen BM, Lomakin A, Bast R, Lu K, Grizzle WE, Jhala NC, Eloubeidi MA, Christein JD, Arnoletti JP, Oelschlager DK, Vickers SM, Marrangoni A, Lokshin A. Abstract 4567: Urine biomarkers outperform serum biomarkers in the diagnosis of various human cancers Cancer Research. 70: 4567-4567. DOI: 10.1158/1538-7445.Am10-4567 |
0.448 |
|
| 2010 |
Landen CN, Goodman B, Nick AM, Stone RL, Meijia PV, Miller LD, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Abstract 4288: Targeted therapy against aldehyde dehydrogenase in ovarian cancer Cancer Research. 70: 4288-4288. DOI: 10.1158/1538-7445.Am10-4288 |
0.495 |
|
| 2010 |
Mandal PK, Liao WS, Gao F, Robertson FM, Thudi NK, Ekmekcioglu S, Chattopadhyay C, Ren Z, Chen X, Lu Z, Bast RC, Ramesh R, McMurray JS. Abstract 2527: Potent, highly selective peptidomimetic prodrugs targeting the SH2 domain of Stat3 decrease vasculogenic mimicry, invasion, and anchorage independent growth of cancer cells Cancer Research. 70: 2527-2527. DOI: 10.1158/1538-7445.Am10-2527 |
0.414 |
|
| 2010 |
Le X, Spizzo R, Mao M, Wu Y, Calin GA, Bast RC. Abstract 2051: DNA (cytosine-5-)-methyltransferases 3A (DNMT3A) is a direct target of miR-194 in breast cancer Cancer Research. 70: 2051-2051. DOI: 10.1158/1538-7445.Am10-2051 |
0.363 |
|
| 2010 |
Ahmed AA, Le X, Lu Z, Mao M, Aiken A, Bast RC. Abstract 1585: Loss of CDK5 sensitizes ovarian cancer cells to paclitaxel by enhancing intracellular retention Cancer Research. 70: 1585-1585. DOI: 10.1158/1538-7445.Am10-1585 |
0.471 |
|
| 2010 |
Keeler ER, Das PM, Bast RC, Lu KH. Ovarian Cancer Screening Clinical Cancer Research. 87-107. DOI: 10.1016/B978-1-4160-4685-1.50011-1 |
0.428 |
|
| 2009 |
Moore RG, MacLaughlan S, Bast RC. Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecologic Oncology. 116: 240-5. PMID 19879639 DOI: 10.1016/J.Ygyno.2009.09.041 |
0.455 |
|
| 2009 |
Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics. 8: 2375-82. PMID 19671744 DOI: 10.1158/1535-7163.Mct-09-0056 |
0.453 |
|
| 2009 |
Samanta AK, Huang HJ, Le XF, Mao W, Lu KH, Bast RC, Liao WS. MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma. Cancer. 115: 3897-908. PMID 19517469 DOI: 10.1002/Cncr.24445 |
0.364 |
|
| 2009 |
Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nature Reviews. Cancer. 9: 415-28. PMID 19461667 DOI: 10.1038/Nrc2644 |
0.386 |
|
| 2009 |
Cheon DJ, Wang Y, Deng JM, Lu Z, Xiao L, Chen CM, Bast RC, Behringer RR. CA125/MUC16 is dispensable for mouse development and reproduction. Plos One. 4: e4675. PMID 19262696 DOI: 10.1371/Journal.Pone.0004675 |
0.369 |
|
| 2009 |
Anderson NS, Bermudez Y, Badgwell D, Chen R, Nicosia SV, Bast RC, Kruk PA. Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecologic Oncology. 112: 60-7. PMID 19007973 DOI: 10.1016/J.Ygyno.2008.09.037 |
0.478 |
|
| 2009 |
Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC, Skates SJ. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology. 112: 40-6. PMID 18851871 DOI: 10.1016/J.Ygyno.2008.08.031 |
0.379 |
|
| 2009 |
Bast RC. Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. Transactions of the American Clinical and Climatological Association. 115: 233-47; discussion 2. PMID 17060970 |
0.361 |
|
| 2008 |
Brown A, Miller C, Robison K, Somers E, Allard J, Granai CO, Skates S, Bast RC, Moore RG. Differential expression of CA125 and a novel serum tumor marker HE4 in epithelial ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5533. PMID 27950487 DOI: 10.1200/Jco.2008.26.15_Suppl.5533 |
0.467 |
|
| 2008 |
Clarke CH, Fung ET, Yip C, Joy C, Badgwell D, Coombes KR, Zhang Z, Lu KH, Bast RC. Use of a panel of proteomic markers to improve the sensitivity of CA125 for detecting stage I epithelial ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5542. PMID 27950480 DOI: 10.1200/Jco.2008.26.15_Suppl.5542 |
0.422 |
|
| 2008 |
Bast RC, Iyer RB, Hu W, Kavanagh J, Coleman RL, Levenback C, Sood AK, Wolf J, Gershenson DM, Markman M, Fu S. A phase IIa study of a sequential regimen using azacitidine to reverse platinum resistance to carboplatin in patients with platinum resistant or refractory epithelial ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3500. PMID 27949577 DOI: 10.1200/Jco.2008.26.15_Suppl.3500 |
0.336 |
|
| 2008 |
Das PM, Bast RC. Early detection of ovarian cancer. Biomarkers in Medicine. 2: 291-303. PMID 20477415 DOI: 10.2217/17520363.2.3.291 |
0.464 |
|
| 2008 |
Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clinical Chemistry. 54: e11-79. PMID 19042984 DOI: 10.1373/Clinchem.2008.105601 |
0.35 |
|
| 2008 |
Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Mills GB, Liao WS, Bast RC. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. The Journal of Clinical Investigation. 118: 3917-29. PMID 19033662 DOI: 10.1172/Jci35512 |
0.487 |
|
| 2008 |
Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, Bast RC. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2 Cell Cycle. 7: 3747-3758. PMID 19029832 DOI: 10.4161/Cc.7.23.7212 |
0.365 |
|
| 2008 |
Wang Y, Cheon DJ, Lu Z, Cunningham SL, Chen CM, Luo RZ, Xing D, Orsulic S, Bast RC, Behringer RR. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. Differentiation; Research in Biological Diversity. 76: 1081-92. PMID 18637025 DOI: 10.1111/J.1432-0436.2008.00295.X |
0.459 |
|
| 2008 |
Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC, Lu K. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecologic Oncology. 110: 196-201. PMID 18495222 DOI: 10.1016/J.Ygyno.2008.04.002 |
0.393 |
|
| 2008 |
Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y, Bast RC. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer. 112: 1489-502. PMID 18286529 DOI: 10.1002/Cncr.23323 |
0.434 |
|
| 2008 |
Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB, Bast RC, Hortobagyi GN, Hung MC. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Molecular Carcinogenesis. 47: 701-6. PMID 18176935 DOI: 10.1002/Mc.20413 |
0.456 |
|
| 2008 |
Ashworth A, Balkwill F, Bast RC, Berek JS, Kaye A, Boyd JA, Mills G, Weinstein JN, Woolley K, Workman P. Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. Gynecologic Oncology. 108: 652-7. PMID 18096210 DOI: 10.1016/J.Ygyno.2007.11.014 |
0.493 |
|
| 2008 |
Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecologic Oncology. 108: 402-8. PMID 18061248 DOI: 10.1016/J.Ygyno.2007.10.017 |
0.444 |
|
| 2008 |
Badgwell D, Bast RC. Early detection of ovarian cancer. Disease Markers. 23: 397-410. PMID 18057523 DOI: 10.1155/2007/309382 |
0.393 |
|
| 2008 |
Das PM, Bast RC. Early detection of ovarian cancer Biomarkers in Medicine. 2: 291-303. DOI: 10.2217/17520363.2.3.291 |
0.359 |
|
| 2007 |
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 5287-312. PMID 17954709 DOI: 10.1200/Jop.0768504 |
0.393 |
|
| 2007 |
Bast RC, Thigpen JT, Arbuck SG, Basen-Engquist K, Burke LB, Freedman R, Horning SJ, Ozols R, Rustin GJ, Spriggs D, Wenzel LB, Pazdur R. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gynecologic Oncology. 107: 173-6. PMID 17950384 DOI: 10.1016/J.Ygyno.2007.08.092 |
0.382 |
|
| 2007 |
Zhang Z, Yu Y, Xu F, Berchuck A, Haaften-Day Cv, Havrilesky LJ, Bruijn HWAd, Zee AGJvd, Woolas RP, Jacobs IJ, Skates S, Chan DW, Bast RC. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer Gynecologic Oncology. 107: 526-531. PMID 17920110 DOI: 10.1016/J.Ygyno.2007.08.009 |
0.46 |
|
| 2007 |
Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC, Shen Y, Issa JP, Yu Y. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Research : Bcr. 9: R57. PMID 17764565 DOI: 10.1186/Bcr1762 |
0.339 |
|
| 2007 |
Moore RG, Bast RC. How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4159-61. PMID 17698803 DOI: 10.1200/Jco.2007.11.9594 |
0.452 |
|
| 2007 |
Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Allard J, Moore RG, Lu KH, Bast RC. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecologic Oncology. 106: 490-7. PMID 17532030 DOI: 10.1016/J.Ygyno.2007.04.022 |
0.417 |
|
| 2007 |
Bast RC, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z, Chan D, Lokshin A, Yu Y. Prevention and early detection of ovarian cancer: mission impossible? Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrã¨S Dans Les Recherches Sur Le Cancer. 174: 91-100. PMID 17302189 DOI: 10.1007/978-3-540-37696-5_9 |
0.498 |
|
| 2007 |
Brewer M, Ranger-Moore J, Satterfield W, Hao Z, Wang J, Brewer E, Wharton JT, Bast R, Zou C. Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian cancer. Frontiers in Bioscience : a Journal and Virtual Library. 12: 2260-8. PMID 17127462 DOI: 10.2741/2228 |
0.376 |
|
| 2007 |
Yang G, Rosen DG, Mercado-Uribe I, Colacino JA, Mills GB, Bast RC, Zhou C, Liu J. Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis. 28: 174-82. PMID 16829690 DOI: 10.1093/Carcin/Bgl115 |
0.414 |
|
| 2007 |
Bast RC. Status of tumor markers in ovarian cancer screening. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 200s-205s. PMID 12743135 DOI: 10.1200/Jco.2003.01.068 |
0.484 |
|
| 2007 |
Le X, Arachchige-Don AS, Mao W, Horne MC, Bast RC. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells Molecular Cancer Therapeutics. 6: 2843-2857. DOI: 10.1158/1535-7163.Mct-07-0109 |
0.354 |
|
| 2006 |
Rosen DG, Mercado-Uribe I, Yang G, Bast RC, Amin HM, Lai R, Liu J. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer. 107: 2730-40. PMID 17063503 DOI: 10.1002/Cncr.22293 |
0.35 |
|
| 2006 |
Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 5313-27. PMID 17060676 DOI: 10.1200/Jco.2006.08.2644 |
0.344 |
|
| 2006 |
Yang G, Rosen DG, Zhang Z, Bast RC, Mills GB, Colacino JA, Mercado-Uribe I, Liu J. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 103: 16472-7. PMID 17060621 DOI: 10.1073/Pnas.0605752103 |
0.508 |
|
| 2006 |
Farley J, Bast RC, Birrer MJ. Biomarkers and clinical trial design. Gynecologic Oncology. 103: S3-5. PMID 17027069 DOI: 10.1016/J.Ygyno.2006.08.017 |
0.308 |
|
| 2006 |
Fu S, Kavanagh JJ, Hu W, Bast RC. Clinical application of oxaliplatin in epithelial ovarian cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 16: 1717-32. PMID 17009963 DOI: 10.1111/J.1525-1438.2006.00654.X |
0.432 |
|
| 2006 |
Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K, Lee MH, Zhao J, Bast RC. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. Cell Cycle (Georgetown, Tex.). 5: 1654-61. PMID 16861913 DOI: 10.4161/Cc.5.15.3007 |
0.358 |
|
| 2006 |
Rosen DG, Yang G, Bast RC, Liu J. Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. Methods in Enzymology. 407: 660-76. PMID 16757360 DOI: 10.1016/S0076-6879(05)07052-7 |
0.39 |
|
| 2006 |
Yu Y, Luo R, Lu Z, Wei Feng W, Badgwell D, Issa JP, Rosen DG, Liu J, Bast RC. Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers. Methods in Enzymology. 407: 455-68. PMID 16757345 DOI: 10.1016/S0076-6879(05)07037-0 |
0.475 |
|
| 2006 |
Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC, Le XF. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene. 25: 6986-96. PMID 16715132 DOI: 10.1038/Sj.Onc.1209685 |
0.323 |
|
| 2006 |
Lu Z, Luo RZ, Peng H, Rosen DG, Atkinson EN, Warneke C, Huang M, Nishmoto A, Liu J, Liao WS, Yu Y, Bast RC. Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2404-13. PMID 16638845 DOI: 10.1158/1078-0432.Ccr-05-1036 |
0.481 |
|
| 2006 |
Brewer M, Kirkpatrick ND, Wharton JT, Wang J, Hatch K, Auersperg N, Utzinger U, Gershenson D, Bast R, Zou C. 4-HPR modulates gene expression in ovarian cells. International Journal of Cancer. 119: 1005-13. PMID 16570282 DOI: 10.1002/Ijc.21797 |
0.467 |
|
| 2006 |
Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB, Urban ND. 10th Biennial Helene Harris Memorial Trust meeting. Cancer Research. 66: 2904-6. PMID 16540635 DOI: 10.1158/0008-5472.Can-05-2093 |
0.336 |
|
| 2006 |
Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, Bast RC, Mills GB, Fang X. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Research. 66: 2740-8. PMID 16510595 DOI: 10.1158/0008-5472.Can-05-2947 |
0.494 |
|
| 2006 |
Fu S, Hu W, Kavanagh JJ, Bast RC. Targeting Aurora kinases in ovarian cancer. Expert Opinion On Therapeutic Targets. 10: 77-85. PMID 16441230 DOI: 10.1517/14728222.10.1.77 |
0.462 |
|
| 2006 |
Zhang Z, Bast RC, Vergote I, Høgdall C, Ueland FR, Van der Zee A, Wang Z, Yip C, Chan DW, Fung ET. A large-scale multi-center independent validation study of a panel of seven biomarkers for the detection of ovarian cancer Journal of Clinical Oncology. 24: 5057-5057. DOI: 10.1200/Jco.2006.24.18_Suppl.5057 |
0.421 |
|
| 2006 |
Moore RG, Brown AK, Miller CM, Badgwell D, Lu Z, Verch T, Allard JW, Granai CO, Bast R, Lu K. Utility of a novel serum tumor biomarker HE4 in patients with uterine cancer Journal of Clinical Oncology. 24: 5036-5036. DOI: 10.1200/Jco.2006.24.18_Suppl.5036 |
0.428 |
|
| 2006 |
Moore RG, Brown AK, Miller CM, Badgwell D, Lu Z, Verch T, Lu KH, Allard JW, Granai CO, Bast R. A novel multiple biomarker assay for the detection of ovarian carcinoma Journal of Clinical Oncology. 24: 5023-5023. DOI: 10.1200/Jco.2006.24.18_Suppl.5023 |
0.47 |
|
| 2006 |
Bast R. Ovarian cancer prevention+early detection: Mission impossible? European Journal of Cancer Supplements. 4: 18. DOI: 10.1016/S1359-6349(06)80488-X |
0.347 |
|
| 2005 |
Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K. New tumor markers: CA125 and beyond. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 15: 274-81. PMID 16343244 DOI: 10.1111/J.1525-1438.2005.00441.X |
0.457 |
|
| 2005 |
Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, Macdonald N, Dawnay A, Jeyarajah A, Bast RC, Oram D, Jacobs IJ. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7919-26. PMID 16258091 DOI: 10.1200/Jco.2005.01.6642 |
0.378 |
|
| 2005 |
Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 6116-26. PMID 16144910 DOI: 10.1158/1078-0432.Ccr-04-2509 |
0.461 |
|
| 2005 |
Nishimoto A, Yu Y, Lu Z, Mao X, Ren Z, Watowich SS, Mills GB, Liao WS, Chen X, Bast RC, Luo RZ. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. Cancer Research. 65: 6701-10. PMID 16061651 DOI: 10.1158/0008-5472.Can-05-0130 |
0.408 |
|
| 2005 |
Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecologic Oncology. 99: 267-77. PMID 16061277 DOI: 10.1016/J.Ygyno.2005.06.040 |
0.486 |
|
| 2005 |
Young T, Mei F, Liu J, Bast RC, Kurosky A, Cheng X. Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model. Oncogene. 24: 6174-84. PMID 15940260 DOI: 10.1038/Sj.Onc.1208753 |
0.352 |
|
| 2005 |
Brewer M, Wharton JT, Wang J, McWatters A, Auersperg N, Gershenson D, Bast R, Zou C. In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer Gynecologic Oncology. 98: 182-192. PMID 15907982 DOI: 10.1016/J.Ygyno.2005.01.051 |
0.481 |
|
| 2005 |
Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 2149-55. PMID 15788660 DOI: 10.1158/1078-0432.Ccr-04-1673 |
0.414 |
|
| 2005 |
Le XF, Pruefer F, Bast RC. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle (Georgetown, Tex.). 4: 87-95. PMID 15611642 DOI: 10.4161/Cc.4.1.1360 |
0.349 |
|
| 2004 |
Bast RC, Hortobagyi GN. Individualized care for patients with cancer - a work in progress. The New England Journal of Medicine. 351: 2865-7. PMID 15591336 DOI: 10.1056/Nejme048300 |
0.443 |
|
| 2004 |
Le XF, Lammayot A, Gold D, Lu Y, Mao W, Chang T, Patel A, Mills GB, Bast RC. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. The Journal of Biological Chemistry. 280: 2092-104. PMID 15504738 DOI: 10.1074/Jbc.M403080200 |
0.358 |
|
| 2004 |
Rosen DG, Wang L, Jain AN, Lu KH, Luo RZ, Yu Y, Liu J, Bast RC. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6559-66. PMID 15475444 DOI: 10.1158/1078-0432.Ccr-04-0698 |
0.498 |
|
| 2004 |
Skates SJ, Horick N, Yu Y, Xu FJ, Berchuck A, Havrilesky LJ, Bruijn HWAD, Zee AGJVD, Woolas RP, Jacobs IJ, Zhang Z, Bast RC. Preoperative Sensitivity and Specificity for Early-Stage Ovarian Cancer When Combining Cancer Antigen CA-125II, CA 15-3, CA 72-4, and Macrophage Colony-Stimulating Factor Using Mixtures of Multivariate Normal Distributions Journal of Clinical Oncology. 22: 4059-4066. PMID 15381683 DOI: 10.1200/Jco.2004.03.091 |
0.371 |
|
| 2004 |
Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Research. 64: 5882-90. PMID 15313933 DOI: 10.1158/0008-5472.Can-04-0746 |
0.487 |
|
| 2004 |
Pusztai L, Krishnamurti S, Perez Cardona J, Sneige N, Esteva FJ, Volchenok M, Breitenfelder P, Kau SW, Takayama S, Krajewski S, Reed JC, Bast RC, Hortobagyi GN. Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer. Cancer Investigation. 22: 248-56. PMID 15199607 DOI: 10.1081/Cnv-120030213 |
0.394 |
|
| 2004 |
Rustin GJS, Bast RC, Kelloff GJ, Barrett JC, Carter SK, Nisen PD, Sigman CC, Parkinson DR, Ruddon RW. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer Clinical Cancer Research. 10: 3919-3926. PMID 15173101 DOI: 10.1158/1078-0432.Ccr-03-0787 |
0.46 |
|
| 2004 |
Kelloff GJ, Bast RC, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Vande Woude GF. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3881-4. PMID 15173097 DOI: 10.1158/1078-0432.Ccr-03-0783 |
0.425 |
|
| 2004 |
Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, ... ... Bast RC, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3291-300. PMID 15161682 DOI: 10.1158/1078-0432.Ccr-03-0409 |
0.48 |
|
| 2004 |
Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, Mills GB, Bast RC. A genetically defined model for human ovarian cancer. Cancer Research. 64: 1655-63. PMID 14996724 DOI: 10.1158/0008-5472.Can-03-3380 |
0.474 |
|
| 2004 |
See HT, Kavanagh JJ, Hu W, Bast RC. Targeted therapy for epithelial ovarian cancer: current status and future prospects. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 13: 701-34. PMID 14675307 DOI: 10.1111/J.1525-1438.2003.13601.X |
0.43 |
|
| 2004 |
Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GB. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. The Journal of Biological Chemistry. 279: 9653-61. PMID 14670967 DOI: 10.1074/Jbc.M306662200 |
0.304 |
|
| 2004 |
Samanta AK, Huang HJ, Bast RC, Liao WS. Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB. The Journal of Biological Chemistry. 279: 7576-83. PMID 14662759 DOI: 10.1074/Jbc.M311659200 |
0.438 |
|
| 2004 |
Yang G, Cai KQ, Thompson-Lanza JA, Bast RC, Liu J. Inhibition of Breast and Ovarian Tumor Growth through Multiple Signaling Pathways by Using Retrovirus-mediated Small Interfering RNA against Her-2/neu Gene Expression Journal of Biological Chemistry. 279: 4339-4345. PMID 14625284 DOI: 10.1074/Jbc.M311153200 |
0.428 |
|
| 2004 |
Balkwill F, Bast R, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G, Souhami R, Urban N, Orsulic S, Smyth J. Erratum to “Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust” [European Journal of Cancer, 39 (2003) 1818–1827] European Journal of Cancer. 40: 628. DOI: 10.1016/J.Ejca.2003.11.005 |
0.415 |
|
| 2003 |
Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Seminars in Oncology. 30: 93-104. PMID 14613030 DOI: 10.1053/J.Seminoncol.2003.08.011 |
0.444 |
|
| 2003 |
Wang L, Hoque A, Luo RZ, Yuan J, Lu Z, Nishimoto A, Liu J, Sahin AA, Lippman SM, Bast RC, Yu Y. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 3660-6. PMID 14506155 |
0.302 |
|
| 2003 |
Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, Lu K, Smith DI, Kalli K, Hartmann LC, McCune K, Fishman D, Broaddus R, Cheng KW, Atkinson EN, ... ... Bast RC, et al. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 3534-45. PMID 14506139 |
0.401 |
|
| 2003 |
Fujii S, Luo RZ, Yuan J, Kadota M, Oshimura M, Dent SR, Kondo Y, Issa JP, Bast RC, Yu Y. Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Human Molecular Genetics. 12: 1791-800. PMID 12874100 DOI: 10.1093/Hmg/Ddg204 |
0.31 |
|
| 2003 |
Shvartsman HS, Lu KH, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK, Mills GB, Bast RC, Gershenson DM, Schmandt R. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecologic Oncology. 90: 44-50. PMID 12821340 DOI: 10.1016/S0090-8258(03)00257-9 |
0.399 |
|
| 2003 |
Luo RZ, Fang X, Marquez R, Liu SY, Mills GB, Liao WS, Yu Y, Bast RC. ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene. 22: 2897-909. PMID 12771940 DOI: 10.1038/Sj.Onc.1206380 |
0.31 |
|
| 2003 |
Cannistra SA, Bast RC, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ, Markman M, McGuire WP, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey PA, et al. Progress in the management of gynecologic cancer: consensus summary statement. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 129s-132s. PMID 12743127 DOI: 10.1200/Jco.2003.04.003 |
0.394 |
|
| 2003 |
Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, Bast RC. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. The Journal of Biological Chemistry. 278: 23441-50. PMID 12700233 DOI: 10.1074/Jbc.M300848200 |
0.329 |
|
| 2003 |
Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Mao M, Wang H, Cheng KW, Nakayama Y, Kuo W, Erickson J, Gershenson D, Kohn EC, ... ... Bast RC, et al. Specific keynote: molecular therapeutics in ovarian cancer. Gynecologic Oncology. 88: S88-92; discussion S. PMID 12586094 DOI: 10.1006/Gyno.2002.6692 |
0.466 |
|
| 2003 |
Ozols RF, Daly MB, Klein-Szanto A, Hamilton TC, Bast RC, Brewer MA. Specific keynote: chemoprevention of ovarian cancer: the journey begins Gynecologic Oncology. 88. PMID 12586088 DOI: 10.1006/Gyno.2002.6686 |
0.488 |
|
| 2003 |
Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC, Kudelka AP, Kavanagh JJ, Giovanella BC. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 845-52. PMID 12576458 |
0.359 |
|
| 2003 |
Brewer MA, Johnson K, Follen M, Gershenson D, Bast R. Prevention of ovarian cancer: Intraepithelial neoplasia Clinical Cancer Research. 9: 20-30. PMID 12538447 |
0.351 |
|
| 2003 |
Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC, Mills GB, Gallick GE. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecologic Oncology. 88: 73-9. PMID 12504632 DOI: 10.1006/Gyno.2002.6851 |
0.4 |
|
| 2003 |
See HT, Kavanagh JJ, Hu W, Bast RC. Targeted therapy for epithelial ovarian cancer: Current status and future prospects International Journal of Gynecologic Cancer. 13: 701-734. DOI: 10.1136/ijgc-00009577-200311000-00001 |
0.318 |
|
| 2003 |
Brewer MA, Zhou J, Wharton JT, Ye J, Bast R, Zou C. Biomarkers of 4-HPR in Response of Ovarian Carcinoma OV-CA 433 Cells The Cancer Journal. 9: 518. DOI: 10.1097/00130404-200311000-00119 |
0.352 |
|
| 2003 |
Balkwill F, Bast R, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G, Souhami R, Urban N, Ursulic S, Smyth J. Current research and treatment for epithelial ovarian cancer A Position Paper from the Helene Harris Memorial Trust European Journal of Cancer. 39: 1818-1827. DOI: 10.1016/S0959-8049(03)00511-2 |
0.418 |
|
| 2002 |
Bao JJ, Le XF, Wang RY, Yuan J, Wang L, Atkinson EN, LaPushin R, Andreeff M, Fang B, Yu Y, Bast RC. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway Cancer Research. 62: 7264-7272. PMID 12499268 |
0.321 |
|
| 2002 |
Brewer M, Utzinger U, Li Y, Atkinson EN, Satterfield W, Auersperg N, Richards-Kortum R, Follen M, Bast R. Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agents. Journal of Biomedical Optics. 7: 20-6. PMID 11818008 DOI: 10.1117/1.1427672 |
0.35 |
|
| 2002 |
Bast RC, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills G. Early detection of ovarian cancer: promise and reality Cancer Treatment and Research. 107: 61-97. PMID 11775462 DOI: 10.1007/978-1-4757-3587-1_3 |
0.472 |
|
| 2002 |
Krämer S, Yu Y, Jäger W, Lang N, Bast RC, Beckmann MW. Characterization of the ARHI Tumor-Suppressor as a Target for Gene Therapy in Ovarian Cancer* Geburtshilfe Und Frauenheilkunde. 62: 870-876. DOI: 10.1055/S-2002-33888 |
0.459 |
|
| 2001 |
Mills GB, Bast RC, Srivastava S. Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. Journal of the National Cancer Institute. 93: 1437-9. PMID 11584052 DOI: 10.1093/Jnci/93.19.1437 |
0.494 |
|
| 2001 |
Brewer M, Utzinger U, Silva E, Gershenson D, Bast RC, Follen M, Richards-Kortum R. Fluorescence spectroscopy for in vivo characterization of ovarian tissue. Lasers in Surgery and Medicine. 29: 128-35. PMID 11553899 DOI: 10.1002/Lsm.1098 |
0.358 |
|
| 2001 |
Donato ML, Gershenson DM, Wharton JT, Ippoliti CM, Aleman AS, Bodurka-Bevers D, Bevers MW, Burke TW, Levenback CF, Wolf JK, Freedman RS, Bast RC, Gajewski JL, Champlin RE. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecologic Oncology. 82: 420-6. PMID 11520135 DOI: 10.1006/Gyno.2001.6326 |
0.341 |
|
| 2001 |
Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL, Willey J, Bast R, Hortobagyi GN. Phase I-II vinorelbine (Navelbine®) by continuous infusion in patients with metastatic breast cancer: Cumulative toxicities limit dose escalation Cancer Investigation. 19: 459-466. PMID 11458813 DOI: 10.1081/Cnv-100103844 |
0.312 |
|
| 2001 |
Luo RZ, Peng H, Xu F, Bao J, Pang Y, Pershad R, Issa JP, Liao WS, Bast RC, Yu Y. Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI. Biochimica Et Biophysica Acta. 1519: 216-22. PMID 11418188 DOI: 10.1016/S0167-4781(01)00226-3 |
0.341 |
|
| 2001 |
Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 1865-78. PMID 11251019 DOI: 10.1200/Jco.2001.19.6.1865 |
0.362 |
|
| 2001 |
Rivera E, Valero V, Syrewicz L, Rahman Z, Esteva FJ, Theriault RL, Rosales MM, Booser D, Murray JL, Bast RC, Hortobagyi GN, Esteva FL. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 1716-22. PMID 11251001 DOI: 10.1200/Jco.2001.19.6.1716 |
0.371 |
|
| 2001 |
Rodriguez GC, Haisley C, Hurteau J, Moser TL, Whitaker R, Bast RC, Stack MS. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. Gynecologic Oncology. 80: 245-53. PMID 11161867 DOI: 10.1006/Gyno.2000.6042 |
0.381 |
|
| 2001 |
Schmidt M, McWatters A, White RA, Groner B, Wels W, Fan Z, Bast RC. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2 Gynecologic Oncology. 80: 145-155. PMID 11161852 DOI: 10.1006/Gyno.2000.6040 |
0.471 |
|
| 2001 |
Cristofanilli M, Fratarcangeli T, Esteva F, Rosales M, Booser D, Ibrahim N, Pusztai L, Bast R, Rivera E, Hortobagyi G. Weekly high-dose paclitaxel(HD-P) has significant antitumor activity in inflammatory breast cancer (IBC) European Journal of Cancer. 37: S173. DOI: 10.1016/S0959-8049(01)81123-0 |
0.358 |
|
| 2000 |
Kruzelock RP, Cuevas BD, Wiener JR, Xu FJ, Yu Y, Cabeza-Arvelaiz Y, Pershouse M, Lovell MM, Killary AM, Mills GB, Bast RC. Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer Oncogene. 19: 6277-6285. PMID 11175342 DOI: 10.1038/Sj.Onc.1204013 |
0.374 |
|
| 2000 |
Einhorn N, Bast R, Knapp R, Nilsson B, Zurawski V, Sjövall K. Long-term follow-up of the Stockholm screening study on ovarian cancer. Gynecologic Oncology. 79: 466-70. PMID 11104621 DOI: 10.1006/Gyno.2000.5983 |
0.444 |
|
| 2000 |
Hogdall EV, Høgdall CK, Tingulstad S, Hagen B, Nustad K, Xu FJ, Bast RC, Jacobs IJ. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. International Journal of Cancer. 89: 519-23. PMID 11102897 DOI: 10.1002/1097-0215(20001120)89:6<519::Aid-Ijc9>3.0.Co;2-# |
0.394 |
|
| 2000 |
Donato ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe J, Korbling M, Boyer J, Bodurka-Bevers D, et al. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplantation. 25: 1137-40. PMID 10849525 DOI: 10.1038/Sj.Bmt.1702421 |
0.348 |
|
| 2000 |
Peng H, Xu F, Pershad R, Hunt KK, Frazier ML, Berchuck A, Gray JW, Hogg D, Bast RC, Yu Y. ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers. International Journal of Cancer. Journal International Du Cancer. 86: 690-4. PMID 10797292 DOI: 10.1002/(Sici)1097-0215(20000601)86:5<690::Aid-Ijc14>3.0.Co;2-K |
0.418 |
|
| 1999 |
Zalutsky MR, Xu FJ, Yu Y, Foulon CF, Zhao XG, Slade SK, Affleck DJ, Bast RC. Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. Nuclear Medicine and Biology. 26: 781-90. PMID 10628557 DOI: 10.1016/S0969-8051(99)00060-8 |
0.38 |
|
| 1999 |
Wolf JK, Mills GB, Bazzet L, Bast RC, Roth JA, Gershenson DM. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecologic Oncology. 75: 261-6. PMID 10525383 DOI: 10.1006/Gyno.1999.5565 |
0.392 |
|
| 1999 |
Boyer CM, Pusztai L, Wiener JR, Xu FJ, Dean GS, Bast BS, O'Briant KC, Greenwald M, DeSombre KA, Bast RC. Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. International Journal of Cancer. Journal International Du Cancer. 82: 525-31. PMID 10404066 DOI: 10.1002/(Sici)1097-0215(19990812)82:4<525::Aid-Ijc10>3.0.Co;2-J |
0.304 |
|
| 1999 |
Zhang Z, Barnhill SD, Zhang H, Xu F, Yu Y, Jacobs I, Woolas RP, Berchuck A, Madyastha KR, Bast RC. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecologic Oncology. 73: 56-61. PMID 10094881 DOI: 10.1006/Gyno.1999.5320 |
0.325 |
|
| 1999 |
Pusztai L, Siddik ZH, Mills GB, Bast RC. Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model. Acta Oncologica (Stockholm, Sweden). 37: 629-40. PMID 10050979 DOI: 10.1080/028418698429964 |
0.332 |
|
| 1999 |
Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast RC. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proceedings of the National Academy of Sciences of the United States of America. 96: 214-9. PMID 9874798 DOI: 10.1073/Pnas.96.1.214 |
0.457 |
|
| 1999 |
Høgdall EV, Høgdall CK, Kjaer SK, Xu F, Yu Y, Bast RC, Blaakaer J, Jacobs IJ. OVX1 Radioimmunoassay Results Are Dependent on the Method of Sample Collection and Storage Clinical Chemistry. 45: 692-694. DOI: 10.1093/Clinchem/45.5.692 |
0.373 |
|
| 1998 |
Gershenson DM, Burke TW, Morris M, Bast RC, Guaspari A, Hohneker J, Wharton JT. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecologic Oncology. 70: 404-409. PMID 9790795 DOI: 10.1006/Gyno.1998.5130 |
0.348 |
|
| 1998 |
Bast RC, Pusztai L, Kerns BJ, MacDonald JA, Jordan P, Daly L, Boyer CM, Mendelsohn J, Berchuck A. Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma. 17: 313-21. PMID 9790065 DOI: 10.1089/Hyb.1998.17.313 |
0.449 |
|
| 1998 |
Boente MP, Berchuck A, Whitaker RS, Kalén A, Xu FJ, Clarke-Pearson DL, Bell RM, Bast RC. Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines. Gynecologic Oncology. 70: 49-55. PMID 9698473 DOI: 10.1006/Gyno.1998.5050 |
0.359 |
|
| 1998 |
Bast RC, Desch CE, Hayes DF, Kemeny NE, Ravdin P, Somerfield MR, Smith TJ. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer Journal of Clinical Oncology. 16: 793-795. PMID 9469371 DOI: 10.1200/Jco.1998.16.2.793 |
0.414 |
|
| 1998 |
Fang X, Jin X, Xu HJ, Liu L, Peng HQ, Hogg D, Roth JA, Yu Y, Xu F, Bast RC, Mills GB. Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene. 16: 1-8. PMID 9467937 DOI: 10.1038/Sj.Onc.1201525 |
0.308 |
|
| 1998 |
Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC, Bast RC. Pathogenesis of ovarian cancers. Journal of the Society For Gynecologic Investigation. 1: 181-90. PMID 9419769 DOI: 10.1177/107155769400100302 |
0.441 |
|
| 1998 |
Bast R, Xu F, Yu Y, Barnhill S, Zhang Z, Mills G. CA 125: The past and the Future The International Journal of Biological Markers. 13: 179-187. DOI: 10.1177/172460089801300402 |
0.41 |
|
| 1998 |
Martell R, Xu F, Davis W, Anselmino L, Yu Y, Daly L, Bast R. OVX1 and CEA in Patients with Colon Carcinoma, Colon Polyps and Benign Colon Disorders The International Journal of Biological Markers. 13: 145-149. DOI: 10.1177/172460089801300304 |
0.371 |
|
| 1998 |
Fritsche HA, Bast RC. CA 125 in Ovarian Cancer: Advances and Controversy Clinical Chemistry. 44: 1379-1380. DOI: 10.1093/Clinchem/44.7.1379 |
0.437 |
|
| 1997 |
Xu HJ, Zhou Y, Ji W, Perng GS, Kruzelock R, Kong CT, Bast RC, Mills GB, Li J, Hu SX. Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition Oncogene. 15: 2589-2596. PMID 9399646 DOI: 10.1038/Sj.Onc.1201446 |
0.374 |
|
| 1997 |
Baile WF, Lenzi R, Kudelka AP, Maguire P, Novack D, Goldstein M, Myers EG, Bast RC. Improving physician-patient communication in cancer care: outcome of a workshop for oncologists. Journal of Cancer Education : the Official Journal of the American Association For Cancer Education. 12: 166-73. PMID 9376255 DOI: 10.1080/08858199709528481 |
0.303 |
|
| 1997 |
Beck EP, Wagner M, Anselmino L, Xu F, Bast RC, Jaeger W. Is OVX1 a suitable marker for endometrial cancer? Gynecologic Oncology. 65: 291-6. PMID 9159340 DOI: 10.1006/Gyno.1997.4620 |
0.362 |
|
| 1997 |
Xu F, Yu Y, Bae D, Zhao X, Slade S, Boyer C, Bast R, Zalutsky M. Radioiodinated antibody targeting of the HER-2/neu oncoprotein Nuclear Medicine and Biology. 24: 451-459. DOI: 10.1016/S0969-8051(97)80014-5 |
0.345 |
|
| 1996 |
Franklin WA, Shpall EJ, Archer P, Johnston CS, Garza-Williams S, Hami L, Bitter MA, Bast RC, Jones RB. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support Breast Cancer Research and Treatment. 41: 1-13. PMID 8932871 DOI: 10.1007/Bf01807031 |
0.387 |
|
| 1996 |
Van Den Brûle FA, Buicu C, Berchuck A, Bast RC, Deprez M, Liu FT, Cooper DNW, Pieters C, Sobel ME, Castronovo V. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma Human Pathology. 27: 1185-1191. PMID 8912829 DOI: 10.1016/S0046-8177(96)90313-5 |
0.465 |
|
| 1996 |
Young TN, Rodriguez GC, Rinehart AR, Bast RC, Pizzo SV, Stack MS. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecologic Oncology. 62: 89-99. PMID 8690299 DOI: 10.1006/Gyno.1996.0195 |
0.359 |
|
| 1996 |
Vredenburgh JJ, Silva O, Tyer C, DeSombre K, Abou-Ghalia A, Cook M, Layfield L, Peters WP, Bast RC. A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow. Journal of Hematotherapy. 5: 57-62. PMID 8646482 DOI: 10.1089/Scd.1.1996.5.57 |
0.35 |
|
| 1996 |
van Haaften-Day C, Russell P, Boyer CM, Kerns BJ, Wiener JR, Jensen DN, Bast RC, Hacker NF. Expression of cell regulatory proteins in ovarian borderline tumors. Cancer. 77: 2092-8. PMID 8640675 DOI: 10.1002/(Sici)1097-0142(19960515)77:10<2092::Aid-Cncr19>3.0.Co;2-Q |
0.358 |
|
| 1996 |
Wiener JR, Kassim SK, Yu Y, Mills GB, Bast RC. Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression. Gynecologic Oncology. 61: 233-40. PMID 8626139 DOI: 10.1006/Gyno.1996.0131 |
0.457 |
|
| 1996 |
Olt G, Soper J, Ramakrishnan S, Xu F, Berchuck A, Clarke-Pearson D, Dodge R, Bast RC. Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer. American Journal of Obstetrics and Gynecology. 174: 1316-9. PMID 8623863 DOI: 10.1016/S0002-9378(96)70678-6 |
0.399 |
|
| 1996 |
Woolas R, Xu F, Jacobs I, Oram D, Bast R. Elevated serum levels of macrophage colony-stimulating factor and OVX1, 11 months prior to the diagnosis of stage IC ovarian cancer International Journal of Gynecological Cancer. 6: 156-158. DOI: 10.1046/J.1525-1438.1996.06020156.X |
0.45 |
|
| 1995 |
Bast RC, Boyer CM, Xu FJ, Wiener J, Dabel R, Woolas R, Jacobs I, Berchuck A. Molecular approaches to prevention and detection of epithelial ovarian cancer. Journal of Cellular Biochemistry. Supplement. 23: 219-22. PMID 8747399 DOI: 10.1002/Jcb.240590929 |
0.508 |
|
| 1995 |
Hurteau JA, Woolas RP, Jacobs IJ, Oram DC, Kurman CC, Rubin LA, Nelson DL, Berchuck A, Bast RC, Mills GB. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer. 76: 1615-20. PMID 8635066 DOI: 10.1002/1097-0142(19951101)76:9<1615::Aid-Cncr2820760918>3.0.Co;2-G |
0.394 |
|
| 1994 |
Jacobs IJ, Rivera H, Oram DH, Bast RC. Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. British Journal of Obstetrics and Gynaecology. 100: 1120-4. PMID 8297846 DOI: 10.1111/J.1471-0528.1993.Tb15177.X |
0.357 |
|
| 1994 |
Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC. The p53 tumor suppressor gene frequently is altered in gynecologic cancers American Journal of Obstetrics and Gynecology. 170: 246-252. PMID 8296829 DOI: 10.1016/S0002-9378(94)70414-7 |
0.411 |
|
| 1994 |
Young TN, Rodriguez GC, Moser TL, Bast RC, Pizzo SV, Stack MS. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. American Journal of Obstetrics and Gynecology. 170: 1285-96. PMID 8178854 DOI: 10.1016/S0002-9378(94)70143-1 |
0.338 |
|
| 1994 |
Wiener JR, Hurteau JA, Kerns BJM, Whitaker RS, Conaway MR, Berchuck A, Bast RC. Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas American Journal of Obstetrics and Gynecology. 170: 1177-1183. PMID 8166206 DOI: 10.1016/S0002-9378(94)70118-0 |
0.375 |
|
| 1994 |
Kerns BJ, Jordan PA, Faerman LL, Berchuck A, Bast RC, Layfield LJ. Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. American Journal of Clinical Pathology. 101: 192-7. PMID 8116574 DOI: 10.1093/Ajcp/101.2.192 |
0.48 |
|
| 1994 |
Moser TL, Young TN, Rodriguez GC, Pizzo SV, Bast RC, Stack MS. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. International Journal of Cancer. Journal International Du Cancer. 56: 552-9. PMID 8112891 DOI: 10.1002/Ijc.2910560415 |
0.352 |
|
| 1994 |
Campbell IG, Nicolai HM, Foulkes WD, Senger G, Stamp GW, Allan G, Boyer C, Jones K, Bast RC, Solomon E. A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. Human Molecular Genetics. 3: 589-94. PMID 8069304 DOI: 10.1093/Hmg/3.4.589 |
0.354 |
|
| 1994 |
Xu FJ, Boyer CM, Bae DS, Wu S, Greenwald M, O'Briant K, Yu YH, Mills GB, Bast RC. The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin. International Journal of Cancer. Journal International Du Cancer. 59: 242-7. PMID 7927925 DOI: 10.1002/Ijc.2910590217 |
0.316 |
|
| 1994 |
Lukes AS, Kohler MF, Pieper CF, Kerns BJ, Bentley R, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC, Berchuck A. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer Cancer. 73: 2380-2385. PMID 7909491 DOI: 10.1002/1097-0142(19940501)73:9<2380::Aid-Cncr2820730922>3.0.Co;2-G |
0.349 |
|
| 1994 |
Wiener JR, Kerns BJM, Harvey EL, Conaway MR, Lglehart JD, Berchuck A, Bast RC. Overexpression of the protien tyrosine phosphatase PTP1B in human breast cancer: Assocation with p185c-erbB-2 protein expression Journal of the National Cancer Institute. 86: 372-378. PMID 7905928 DOI: 10.1093/Jnci/86.5.372 |
0.427 |
|
| 1994 |
van den Brûle FA, Berchuck A, Bast RC, Liu FT, Gillet C, Sobel ME, Castronovo V. Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas European Journal of Cancer. 30: 1096-1099. PMID 7654437 DOI: 10.1016/0959-8049(94)90464-2 |
0.462 |
|
| 1994 |
Berchuck A, Kohler MF, Hopkins MP, Humphrey PA, Robboy SJ, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecologic Oncology. 52: 232-6. PMID 7508877 DOI: 10.1006/Gyno.1994.1037 |
0.373 |
|
| 1994 |
Kerns BM, Jordan PA, Faerman LL, Berchuck A, Bast RC, Layfield LJ. Determination of Proliferation Index with MIB-1 in Advanced Ovarian Cancer Using Quantitative Image Analysis American Journal of Clinical Pathology. 101: 192-197. DOI: 10.1093/AJCP/101.2.192 |
0.309 |
|
| 1994 |
Berchuck A, Kohler M, Marks J, Wiseman R, Boyd J, Bast R. The p53 tumor suppressor gene frequently is altered in gynecologic cancers International Journal of Gynecology & Obstetrics. 47: 201-201. DOI: 10.1016/0020-7292(94)90398-0 |
0.406 |
|
| 1993 |
Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC, Jones R, Shpall E. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 11: 1132-43. PMID 8501500 DOI: 10.1200/Jco.1993.11.6.1132 |
0.323 |
|
| 1993 |
Bast RC, Boyer CM, Jacobs I, Xu FJ, Wu S, Wiener J, Kohler M, Berchuck A. Cell growth regulation in epithelial ovarian cancer. Cancer. 71: 1597-601. PMID 8431895 DOI: 10.1002/CNCR.2820710426 |
0.344 |
|
| 1993 |
Berchuck A, Kohler MF, Boente MP, Rodriguez GC, Whitaker RS, Bast RC. Growth regulation and transformation of ovarian epithelium. Cancer. 71: 545-51. PMID 8420675 DOI: 10.1002/CNCR.2820710209 |
0.312 |
|
| 1993 |
Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-pearson DL, Soper JT, Bast RC, Berchuck A. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer Journal of the National Cancer Institute. 85: 1513-1519. PMID 8360934 DOI: 10.1093/Jnci/85.18.1513 |
0.384 |
|
| 1993 |
Lidor YJ, Xu FJ, Martínez-Maza O, Olt GJ, Marks JR, Berchuck A, Ramakrishnan S, Berek JS, Bast RC. Constitutive Production of Macrophage Colony-Stimulating Factor and Interleukin-6 by Human Ovarian Surface Epithelial Cells Experimental Cell Research. 207: 332-339. PMID 8344385 DOI: 10.1006/Excr.1993.1200 |
0.383 |
|
| 1993 |
Bast R, Woolas R. Screening for ovarian cancer. Multiple markers may outperform CA 125 alone. Bmj (Clinical Research Ed.). 306: 1684-5. PMID 8324445 DOI: 10.1136/Bmj.306.6893.1684-B |
0.43 |
|
| 1993 |
Jordan PA, Kerns BJ, Pence JC, Kohler MF, Bast RC, Kinney RB, Berchuck A. Determination of proliferation index in advanced ovarian cancer using quantitative image analysis. American Journal of Clinical Pathology. 99: 736-40. PMID 8322710 DOI: 10.1093/Ajcp/99.6.736 |
0.486 |
|
| 1993 |
Lidor YJ, O'Briant KC, Xu FJ, Hamilton TC, Ozols RF, Bast RC. Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action Journal of Clinical Investigation. 92: 2440-2447. PMID 8227359 DOI: 10.1172/Jci116851 |
0.389 |
|
| 1993 |
Boente MP, Hurteau J, Rodriguez GC, Bast RC, Berchuck A. The biology of ovarian cancer. Current Opinion in Oncology. 5: 900-7. PMID 8218503 DOI: 10.1097/00001622-199309000-00020 |
0.453 |
|
| 1993 |
McKenzie SJ, DeSombre KA, Bast BS, Hollis DR, Whitaker RS, Berchuck A, Boyer CM, Bast RC. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer. 71: 3942-6. PMID 8099528 DOI: 10.1002/1097-0142(19930615)71:12<3942::Aid-Cncr2820711224>3.0.Co;2-3 |
0.449 |
|
| 1993 |
Xu F, Lupu R, Rodriguez GC, Whitaker RS, Boente MP, Berchuck A, Yu Y, DeSombre KA, Boyer CM, Bast RC. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. International Journal of Cancer. Journal International Du Cancer. 53: 401-8. PMID 7679090 DOI: 10.1002/Ijc.2910530310 |
0.32 |
|
| 1993 |
Wiener JR, Berchuck A, Bast RC. Biology and therapy with biologic agents in gynecologic cancer. Current Opinion in Oncology. 4: 946-54. PMID 1457511 DOI: 10.1097/00001622-199210000-00020 |
0.42 |
|
| 1993 |
Woolas RP, Xu F, Jacabs IJ, Yu Y, Daly L, Brechuck A, Soper JT, Clarke-pearson DL, Oram DH, Bast RC. Elevation of Multiple Serum Markers in Patients With Stage I Ovarian Cancer Jnci Journal of the National Cancer Institute. 85: 1748-1751. DOI: 10.1093/Jnci/85.21.1748 |
0.473 |
|
| 1993 |
Bast RC. Perspectives on the future of cancer markers Clinical Chemistry. 39: 2444-2451. DOI: 10.1093/Clinchem/39.11.2444 |
0.543 |
|
| 1993 |
Rodriguez GC, Boente MP, Berchuck A, Whitaker RS, O’Briant KC, Xu F, Bast RC. The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines American Journal of Obstetrics and Gynecology. 168: 228-232. DOI: 10.1016/S0002-9378(12)90918-7 |
0.438 |
|
| 1993 |
Einhorn N, Sjovall K, Knapp R, Hall K, Scully R, Bast R, Zurawski V. 92225921 Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer Maturitas. 16: 88. DOI: 10.1016/0378-5122(93)90150-G |
0.439 |
|
| 1993 |
Jacobs I, Oram D, Bast R. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3 International Journal of Gynecology & Obstetrics. 41: 214-214. DOI: 10.1016/0020-7292(93)90735-F |
0.41 |
|
| 1993 |
Boente M, Berchuck A, Rodriguez G, Davidoff A, Whitaker R, Xu F, Marks J, Clarke-Pearson D, Bast R. The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells International Journal of Gynecology & Obstetrics. 42: 226-227. DOI: 10.1016/0020-7292(93)90683-N |
0.324 |
|
| 1992 |
Daly L, Ferguson J, Cram GP, Hars V, George SL, McCarty KS, Bast RC. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 10: 1057-65. PMID 1607912 DOI: 10.1200/Jco.1992.10.7.1057 |
0.409 |
|
| 1992 |
Kerns BJ, Jordan PA, Moore MB, Humphrey PA, Berchuck A, Kohler MF, Bast RC, Iglehart JD, Marks JR. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 40: 1047-51. PMID 1607637 DOI: 10.1177/40.7.1607637 |
0.409 |
|
| 1992 |
Bast RC, Jacobs I, Berchuck A. Malignant transformation of ovarian epithelium. Journal of the National Cancer Institute. 84: 556-8. PMID 1556762 DOI: 10.1093/Jnci/84.8.556 |
0.458 |
|
| 1992 |
Wu S, Rodabaugh K, Martinez-Maza O, Watson JM, Silberstein DS, Boyer CM, Peters WP, Weinberg JB, Berek JS, Bast RC. Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. American Journal of Obstetrics and Gynecology. 166: 997-1007. PMID 1550178 DOI: 10.1016/0002-9378(92)91379-O |
0.392 |
|
| 1992 |
Berchuck A, Rodriguez G, Olt G, Whitaker R, Boente MP, Arrick BA, Clarke-Pearson DL, Bast RC. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. American Journal of Obstetrics and Gynecology. 166: 676-84. PMID 1536252 DOI: 10.1016/0002-9378(92)91697-9 |
0.362 |
|
| 1992 |
Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BAJ, Humphrey P, Berchuck A, Ponder BAJ, Bast RC. Clonal origin of epithelial ovarian carcinoma: Analysis by loss of heterozygosity, p53 mutation, and x-chromosome inactivation Journal of the National Cancer Institute. 84: 1793-1798. PMID 1433368 DOI: 10.1093/Jnci/84.23.1793 |
0.457 |
|
| 1992 |
Olt G, Berchuck A, Soisson AP, Boyer CM, Bast RC. Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer. Cancer. 70: 2137-42. PMID 1394043 DOI: 10.1002/1097-0142(19921015)70:8<2137::AID-CNCR2820700821>3.0.CO;2-W |
0.363 |
|
| 1992 |
Deutsch MA, Pence JC, Kerns BJ, Plate CA, Kinney R, Gooch G, Iglehart JD, Bast RC. Detection of a novel marker in the bronchial secretions of patients with non-small cell lung cancer using the 4B5 monoclonal antibody. Cancer. 69: 2894-904. PMID 1375528 DOI: 10.1002/1097-0142(19920615)69:12<2894::Aid-Cncr2820691206>3.0.Co;2-L |
0.346 |
|
| 1992 |
Berchuck A, Boente MP, Kerns BJ, Kinney RB, Soper JT, Clarke-Pearson DL, Bast RC, Bacus SS. Ploidy analysis of epithelial ovarian cancers using image cytometry Gynecologic Oncology. 44: 61-65. PMID 1370427 DOI: 10.1016/0090-8258(92)90013-9 |
0.463 |
|
| 1992 |
Berchuck A, Kohler MF, Bast RC. Oncogenes in Ovarian Cancer Hematology/Oncology Clinics of North America. 6: 813-827. DOI: 10.1016/S0889-8588(18)30311-3 |
0.495 |
|
| 1992 |
Wu S, Rodabaugh K, Martinez-Maza O, Watson J, Silberstein D, Boyer C, Peters W, Weinberg J, Berek J, Bast R. Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6 and tumor necrosis factor-α International Journal of Gynecology & Obstetrics. 39: 250-250. DOI: 10.1016/0020-7292(92)90680-H |
0.319 |
|
| 1992 |
Rodriguez G, Berchuck A, Whitaker R, Schlossman D, Clarke-Pearson D, Bast R. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor International Journal of Gynecology & Obstetrics. 37: 158-158. DOI: 10.1016/0020-7292(92)90528-Q |
0.353 |
|
| 1991 |
Olt GJ, Berchuck A, Bast RC. Gynecologic tumor markers. Seminars in Surgical Oncology. 6: 305-13. PMID 2263805 DOI: 10.1002/Ssu.2980060604 |
0.419 |
|
| 1991 |
Rodriguez GC, Berchuck A, Whitaker RS, Schlossman D, Clarke-Pearson DL, Bast RC. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. American Journal of Obstetrics and Gynecology. 164: 745-50. PMID 2003535 DOI: 10.1016/0002-9378(91)90508-O |
0.375 |
|
| 1991 |
Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL, Bast RC. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. American Journal of Obstetrics and Gynecology. 164: 669-74. PMID 1992720 DOI: 10.1016/S0002-9378(11)80044-X |
0.413 |
|
| 1991 |
Shpall EJ, Jones RB, Bast RC, Rosner GL, Vandermark R, Ross M, Affronti ML, Johnston C, Eggteston S, Tepperburg M, Coniglio D, Peters WP. 4-hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: A phase I trial Journal of Clinical Oncology. 9: 85-93. PMID 1985173 DOI: 10.1200/Jco.1991.9.1.85 |
0.353 |
|
| 1991 |
Lidor YJ, Shpall EJ, Peters WP, Bast RC. Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. International Journal of Cancer. 49: 704-10. PMID 1937956 DOI: 10.1002/Ijc.2910490513 |
0.391 |
|
| 1991 |
Bast RC, Knauf S, Epenetos A, Dhokia B, Daly L, Tanner M, Soper J, Creasman W, Gall S, Knapp RC. Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer. 68: 1758-63. PMID 1913520 DOI: 10.1002/1097-0142(19911015)68:8<1758::Aid-Cncr2820680819>3.0.Co;2-# |
0.439 |
|
| 1991 |
O'Briant KC, Shpall EJ, Houston LL, Peters WP, Bast RC. Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres. Cancer. 68: 1272-8. PMID 1873781 DOI: 10.1002/1097-0142(19910915)68:6<1272::Aid-Cncr2820680616>3.0.Co;2-L |
0.402 |
|
| 1991 |
WELCH WR, NILOFF JM, ANDERSON D, BATTAILE A, EMERY S, KNAPP RC, BAST RC. Antigenic Heterogeneity in Human Ovarian Cancer Obstetrical & Gynecological Survey. 46: 59-60. DOI: 10.1097/00006254-199101000-00019 |
0.348 |
|
| 1991 |
Xu F, Ramakrishnan S, Daly L, Soper J, Berchuck A, Clarke-Pearson D, Bast R. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer American Journal of Obstetrics and Gynecology. 165: 1356-1362. DOI: 10.1016/S0002-9378(12)90761-9 |
0.403 |
|
| 1991 |
Berchuck A, Rodriguez G, Olt G, Arrick B, Clarke-Pearson D, Bast R. Regulation of growth of normal ovarian epithelium and ovarian cancer cell lines by transforming growth factor-β Gynecologic Oncology. 40: 182. DOI: 10.1016/0090-8258(91)90173-3 |
0.385 |
|
| 1991 |
Zurawski V, Sjovall K, Schoenfeld D, Broderick S, Hall P, Bast R, Eklund G, Mattsson B, Connor R, Prorok P, Knapp R, Einhorn N. Prospective evaluation of serum CA 125 levels in abnormal population, phase I: The specificites of single and serial determination in testing for ovarian cancer International Journal of Gynecology & Obstetrics. 34: 92-93. DOI: 10.1016/0020-7292(91)90584-R |
0.399 |
|
| 1991 |
Berchuck A, Olt G, Soisson A, Kamel A, Soper J, Boyer C, Clarke-Pearson D, Leslie D, Bast R. Heterogeneity of antigen expression in advanced epithelial ovarian cancer International Journal of Gynecology & Obstetrics. 34: 192-193. DOI: 10.1016/0020-7292(91)90259-8 |
0.468 |
|
| 1991 |
Berchuck A, Rodriguez G, Kinney R, Soper J, Dodge R, Clarke-Pearson D, Bast R. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease International Journal of Gynecology & Obstetrics. 36: 265-265. DOI: 10.1016/0002-9378(91)90615-X |
0.45 |
|
| 1990 |
Soisson AP, Berchuck A, Lessey BA, Soper JT, Clarke-Pearson DL, McCarty KS, Bast RC. Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels. American Journal of Obstetrics and Gynecology. 161: 1258-63. PMID 2589448 DOI: 10.1016/0002-9378(89)90678-9 |
0.317 |
|
| 1990 |
Hunter VJ, Weinberg JB, Haney AF, Soper JT, Lavin P, Metsch L, Knapp RC, Bast RC. CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. Gynecologic Oncology. 36: 161-5. PMID 2404835 DOI: 10.1016/0090-8258(90)90165-H |
0.425 |
|
| 1990 |
Berchuck A, Olt GJ, Soisson AP, Kamel A, Soper JT, Boyer CM, Clarke-Pearson DL, Leslie DS, Bast RC. Heterogeneity of antigen expression in advanced epithelial ovarian cancer. American Journal of Obstetrics and Gynecology. 162: 883-8. PMID 2327461 DOI: 10.1016/0002-9378(90)91288-N |
0.426 |
|
| 1990 |
Zurawski VR, Sjovall K, Schoenfeld DA, Broderick SF, Hall P, Bast RC, Eklund G, Mattsson B, Connor RJ, Prorok PC. Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecologic Oncology. 36: 299-305. PMID 2318438 DOI: 10.1016/0090-8258(90)90130-D |
0.356 |
|
| 1990 |
Soper JT, Berchuck A, Olt GJ, Soisson AP, Clarke-Pearson DL, Bast RC. Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. American Journal of Obstetrics and Gynecology. 163: 1204-9. PMID 2220931 DOI: 10.1016/0002-9378(90)90692-Z |
0.335 |
|
| 1990 |
Leslie DS, Johnston WW, Daly L, Ring DB, Shpall EJ, Peters WP, Bast RC. Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology. American Journal of Clinical Pathology. 94: 8-13. PMID 2193508 DOI: 10.1093/Ajcp/94.1.8 |
0.358 |
|
| 1990 |
Hunter VJ, Daly L, Helms M, Soper JT, Berchuck A, Clarke-Pearson DL, Bast RC. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. American Journal of Obstetrics and Gynecology. 163: 1164-7. PMID 2171337 DOI: 10.1016/0002-9378(90)90680-6 |
0.402 |
|
| 1990 |
Welch WR, Niloff JM, Anderson D, Battaile A, Emery S, Knapp RC, Bast RC. Antigenic heterogeneity in human ovarian cancer. Gynecologic Oncology. 38: 12-6. PMID 2162315 DOI: 10.1097/00006254-199101000-00019 |
0.391 |
|
| 1990 |
Shpall EJ, Clarke-Pearson D, Soper JT, Berchuck A, Jones RB, Bast RC, Ross M, Lidor Y, Vanacek K, Tyler T. High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecologic Oncology. 38: 386-91. PMID 2121627 DOI: 10.1016/0090-8258(90)90079-Z |
0.431 |
|
| 1990 |
OLT G, BERCHUCK A, BAST RC. The Role of Tumor Markers in Gynecologic Oncology Obstetrical & Gynecological Survey. 45: 570-577. DOI: 10.1097/00006254-199009000-00002 |
0.389 |
|
| 1989 |
Zalutsky MR, Knapp RC, Bast RC. Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody. International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology. 15: 431-7. PMID 3255739 DOI: 10.1016/0883-2897(88)90014-1 |
0.301 |
|
| 1989 |
Zalutsky MR, Bast RC, Knapp RC. Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen. International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology. 16: 405-11. PMID 2777582 DOI: 10.1016/0883-2897(89)90108-6 |
0.307 |
|
| 1989 |
Jacobs I, Bast RC. The CA 125 tumour-associated antigen: a review of the literature. Human Reproduction (Oxford, England). 4: 1-12. PMID 2651469 DOI: 10.1093/Oxfordjournals.Humrep.A136832 |
0.424 |
|
| 1989 |
Ramakrishnan S, Xu FJ, Brandt SJ, Niedel JE, Bast RC, Brown EL. Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. The Journal of Clinical Investigation. 83: 921-6. PMID 2646321 DOI: 10.1172/Jci113977 |
0.387 |
|
| 1989 |
Einhorn N, Knapp RC, Bast RC, Zurawski VR. CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary. Acta Oncologica (Stockholm, Sweden). 28: 655-7. PMID 2590540 DOI: 10.3109/02841868909092288 |
0.337 |
|
| 1989 |
Boyer CM, Borowitz MJ, McCarty KS, Kinney RB, Everitt L, Dawson DV, Ring D, Bast RC. Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells. International Journal of Cancer. Journal International Du Cancer. 43: 55-60. PMID 2463226 DOI: 10.1002/Ijc.2910430113 |
0.412 |
|
| 1989 |
Malkasian G, Knapp R, Lavin P, Zurawski V, Podratz K, Stanhope C, Mortel R, Berek J, Bast R, Ritts R. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: Discrimination of benign from malignant disease International Journal of Gynecology & Obstetrics. 28: 392-392. DOI: 10.1016/S0002-9378(88)80081-4 |
0.391 |
|
| 1989 |
Berchuck A, Soisson A, Soper J, Clarke-Pearson D, McCarty K, Bast R. Cellular expression of CA 125 and metastatic potential of endometrial adenocarcinoma Gynecologic Oncology. 32: 103-104. DOI: 10.1016/0090-8258(89)90899-8 |
0.319 |
|
| 1988 |
Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP, Moore JO. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 6: 1368-76. PMID 3047332 DOI: 10.1200/Jco.1988.6.9.1368 |
0.349 |
|
| 1988 |
Zurawski VR, Knapp RC, Einhorn N, Kenemans P, Mortel R, Ohmi K, Bast RC, Ritts RE, Malkasian G. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecologic Oncology. 30: 7-14. PMID 2452773 DOI: 10.1016/0090-8258(88)90039-X |
0.343 |
|
| 1988 |
Knauf S, Bast R. Tumor Antigen Nb/70K and Ca 125 Levels in the Blood of Preoperative Ovarian Cancer Patients and Controls: A Preliminary Report of the use of the Nb12123 and Ca 125 Radioimmunoassays Alone and in Combination The International Journal of Biological Markers. 3: 75-81. DOI: 10.1177/172460088800300201 |
0.469 |
|
| 1987 |
Leoni F, Bast RC, Canevari S, Menard S, Soper JT, Colnaghi MI. Immunochemical characterization and radioimmunometric detection of molecules shed by human ovarian cancer. International Journal of Cancer. 40: 592-7. PMID 2445699 DOI: 10.1002/Ijc.2910400503 |
0.354 |
|
| 1987 |
Bast RC, Hunter V, Knapp RC. Pros and cons of gynecologic tumor markers. Cancer. 60: 1984-92. PMID 2443235 DOI: 10.1002/1097-0142(19901015)60:8+<1984::Aid-Cncr2820601510>3.0.Co;2-W |
0.409 |
|
| 1987 |
Lan MS, Bast RC, Colnaghi MI, Knapp RC, Colcher D, Schlom J, Metzgar RS. Co-expression of human cancer-associated epitopes on mucin molecules. International Journal of Cancer. 39: 68-72. PMID 2432019 DOI: 10.1002/Ijc.2910390112 |
0.359 |
|
| 1986 |
Niloff JM, Knapp RC, Lavin PT, Malkasian GD, Berek JS, Mortel R, Whitney C, Zurawski VR, Bast RC. The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. American Journal of Obstetrics and Gynecology. 155: 56-60. PMID 3460341 DOI: 10.1016/0002-9378(86)90077-3 |
0.363 |
|
| 1986 |
Barbieri RL, Niloff JM, Bast RC, Scaetzl E, Kistner RW, Knapp RC. Elevated serum concentrations of CA-125 in patients with advanced endometriosis. Fertility and Sterility. 45: 630-4. PMID 3457709 DOI: 10.1016/S0015-0282(16)49333-7 |
0.345 |
|
| 1986 |
BEREK JS, KNAPP RC, MALKASIAN GD, LAVIN PT, WHITNEY C, NILOFF JM, BAST RC. CA 125 Serum Levels Correlated With Second-Look Operations Among Ovarian Cancer Patients Obstetrics & Gynecology. 67: 685-689. DOI: 10.1097/00006250-198605000-00016 |
0.361 |
|
| 1986 |
Berek J, Knapp R, Malkasian G, Lavin P, Hacker N, Whitney C, Niloff J, Bast R. CA 125 serum levels correlate with second-look operations among ovarian cancer patients: A prospective multi-institutional study Gynecologic Oncology. 23: 260-261. DOI: 10.1016/0090-8258(86)90273-8 |
0.42 |
|
| 1985 |
Mahvi DM, Meyers WC, Bast RC, Seigler HF, Metzgar RS. Carcinoma of the pancreas. Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody. Annals of Surgery. 202: 440-5. PMID 4051597 DOI: 10.1097/00000658-198510000-00005 |
0.362 |
|
| 1985 |
Bast RC, Knapp RC. Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 19: 354-6. PMID 4018373 DOI: 10.1016/0028-2243(85)90130-3 |
0.329 |
|
| 1985 |
Niloff JM, Bast RC, Schaetzl EM, Knapp RC. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. American Journal of Obstetrics and Gynecology. 151: 981-6. PMID 3157319 DOI: 10.1016/0002-9378(85)90678-7 |
0.372 |
|
| 1985 |
Berek JS, Knapp RC, Hacker NF, Lichtenstein A, Jung T, Spina C, Obrist R, Griffiths CT, Berkowitz RS, Parker L, Zighelboim J, Bast RC. Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum American Journal of Obstetrics and Gynecology. 152: 1003-1010. PMID 2992276 DOI: 10.1016/0002-9378(85)90548-4 |
0.368 |
|
| 1985 |
Sekine H, Hayes DF, Ohno T, Keefe KA, Schaetzl E, Bast RC, Knapp R, Kufe DW. Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 3: 1355-63. PMID 2413181 DOI: 10.1200/Jco.1985.3.10.1355 |
0.466 |
|
| 1985 |
Knauf S, Anderson DJ, Knapp RC, Bast RC. A study of the NB/7OK and CA 125 monoclonal antibody radioimmunoassays for measuring serum antigen levels in ovarian cancer patients. American Journal of Obstetrics and Gynecology. 152: 911-3. PMID 2411137 DOI: 10.1016/S0002-9378(85)80091-0 |
0.367 |
|
| 1985 |
Bast RC, Siegal FP, Runowicz C, Klug TL, Zurawski VR, Schonholz D, Cohen CJ, Knapp RC. Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecologic Oncology. 22: 115-20. PMID 2410329 DOI: 10.1016/0090-8258(85)90015-0 |
0.387 |
|
| 1985 |
Bast RC, Knapp RC. Monitoring Epithelial Ovarian Cancer Laboratory Medicine. 16: 315-318. DOI: 10.1093/Labmed/16.5.315 |
0.483 |
|
| 1985 |
Knapp R, Lavin P, Schaetzl E, Niloff J, Bast R. Elevation of CA-125 prior to recurrence of ovarian cancer Gynecologic Oncology. 20: 263-264. DOI: 10.1016/0090-8258(85)90191-X |
0.454 |
|
| 1984 |
Feig LA, Bast RC, Knapp RC, Cooper GM. Somatic activation of rasK gene in a human ovarian carcinoma Science. 223: 698-701. PMID 6695178 DOI: 10.1126/Science.6695178 |
0.317 |
|
| 1984 |
Gubin N, Ganz PA, Bast RC, Knapp RC. A Radioimmunoassay for Ovarian Cancer The New England Journal of Medicine. 310: 724-725. PMID 6583507 DOI: 10.1056/Nejm198403153101118 |
0.484 |
|
| 1984 |
Niloff JM, Klug TL, Schaetzl E, Zurawski VR, Knapp RC, Bast RC. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. American Journal of Obstetrics and Gynecology. 148: 1057-8. PMID 6201072 DOI: 10.1016/S0002-9378(84)90444-7 |
0.418 |
|
| 1984 |
BAST RC, KLUG TL, JOHN ES, JENISON E, NILOFF JM, LAZARUS H, BERKOWTIZ RS, ZURAWSKI VR, KNAPP RC, LEAVITT T, GRIFFITHS CT, PARKER L. A Radioimmunoassay Using a Monoclonal Antibody To Monitor the Course of Epithelial Ovarian Cancer Obstetrical & Gynecological Survey. 39: 169-170. DOI: 10.1097/00006254-198403000-00020 |
0.315 |
|
| 1984 |
Bast RC, Klug TL, Schaetzl E, Lavin P, Niloff JM, Greber TF, Zurawski VR, Knapp RC. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen American Journal of Obstetrics and Gynecology. 149: 553-559. DOI: 10.1016/0002-9378(84)90035-8 |
0.345 |
|
| 1983 |
Obrist R, Reilly R, Leavitt T, Knapp RC, Bast RC. Monocyte chemotaxis mediated by formyl-methionyl-leucyl-phenylalanine conjugated with monoclonal antibodies against human ovarian carcinoma. International Journal of Immunopharmacology. 5: 307-14. PMID 6629591 DOI: 10.1016/0192-0561(83)90033-4 |
0.332 |
|
| 1983 |
Berkowitz R, Kabawat S, Lazarus H, Colvin R, Knapp R, Bast RC. Comparison of a rabbit heteroantiserum and a murine monoclonal antibody raised against a human epithelial ovarian carcinoma cell line. American Journal of Obstetrics and Gynecology. 146: 607-12. PMID 6346879 DOI: 10.1016/0002-9378(83)90999-7 |
0.363 |
|
| 1983 |
Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. The New England Journal of Medicine. 309: 883-7. PMID 6310399 DOI: 10.1056/Nejm198310133091503 |
0.412 |
|
| 1983 |
Knapp RC, Knapp RC, John ES, Bast RC. A Review of Intraperitoneal Therapy of Human Ovarian Carcinoma Peritoneal Dialysis International: Journal of the International Society For Peritoneal Dialysis. 3: 59-62. DOI: 10.1177/089686088300300204 |
0.378 |
|
| 1983 |
Kabawat SE, Bast RC, Welch WR, Knapp RC, Colvin RB. Immunopathologic Characterization of a Monoclonal Antibody that Recognizes Common Surface Antigens of Human Ovarian Tumors of Serous, Endometrioid, and Clear Cell Types American Journal of Clinical Pathology. 79: 98-104. DOI: 10.1093/Ajcp/79.1.98 |
0.375 |
|
| 1983 |
Kabawat SE, Bast RC, Welch WR, Knapp RC, Bhan AK. Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms International Journal of Cancer. 32: 547-554. DOI: 10.1002/Ijc.2910320505 |
0.355 |
|
| 1981 |
Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. Journal of Clinical Investigation. 68: 1331-1337. PMID 7028788 DOI: 10.1172/Jci110380 |
0.376 |
|
| 1980 |
Bast RC, Knapp RC, Donahue VC, Thurston JG, Mitchell AK, Feeney M, Schlossman SF. Specificity of heteroantisera developed against purified populations of intact murine ovarian carcinoma cells. Journal of the National Cancer Institute. 64: 365-72. PMID 6986493 DOI: 10.1093/Jnci/64.2.365 |
0.346 |
|
| 1980 |
Frei E, Blum RH, Pitman SW, Kirkwood JM, Henderson IC, Skarin AT, Mayer RJ, Bast RC, Garnick MB, Parker LM, Canellos GP. High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity The American Journal of Medicine. 68: 370-376. PMID 6965819 DOI: 10.1016/0002-9343(80)90105-9 |
0.445 |
|
| 1975 |
Bast RC, Zbar B, Mackaness GB, Rapp HJ. Antitumor Activity of Bacterial Infection. I. Effect of Listeria monocytogenes on Growth of a Murine Fibrosarcoma Journal of the National Cancer Institute. 54: 749-756. DOI: 10.1093/Jnci/54.3.749 |
0.302 |
|
| 1974 |
Bast RC, Zbar B, Borsos T, Rapp HJ. BCG and cancer (first of two parts). The New England Journal of Medicine. 290: 1413-20. PMID 4364286 DOI: 10.1056/Nejm197406202902506 |
0.375 |
|
| 1974 |
Bast RC, Zbar B, Borsos T, Rapp HJ. BCG and Cancer New England Journal of Medicine. 290: 1458-1469. DOI: 10.1056/Nejm197406272902605 |
0.456 |
|
| Show low-probability matches. |